Short  Title: Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced 
Urothelial Carcinoma (PemCab)  
Version Date: 30MAR2022  
 
Page [ADDRESS_799602] -Line Therapy for Cisplatin -Ineligible 
Advanced Urothelial Carcinoma  (PemCab)  
CTO ID # HCI -17-GU-10 – Lead Trial ID # HCI104688 – IRB # [ADDRESS_799603] of Hope Salt Lake City, UT  [ZIP_CODE] 
Phone: [PHONE_6739] 
Email: Neeraj. [EMAIL_11516]  
Statistician(s)  Kenneth M.  Boucher, PhD  
Statistician  
Research Associate Professor, Internal Medicine  
Huntsman Cancer Institute - University of Utah 2000 Circle of Hope Room 1710 
Email: Ken.Boucher @hci.utah.edu  
Medical Monitor  Paul Shami, MD  
Coordinating Center Site 
Contact [CONTACT_603860]  
2000 Circle of Hope Salt Lake City, UT [ZIP_CODE] 
[EMAIL_11517]
  
 
Drug Manufacturer  Exelixis  
Drug Manufacturer Protocol 
ID IST-071 
Investigational agent (s) Cabozantinib  
Commercial agent(s)  Pembrolizumab  
IND Number  [ADDRESS_799604] Number (CT.gov)  03534804  
Historical Protocol Versions  
Version 1: 10JU L2018 
Version 2: 25SEP2018 
Short Title:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced Urothelial 
Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page 2 of 82 Version 3: 15MAY2019  
Version 4: 19SEP2019 
Version 5: 19FEB2020  
Version 6: 09JUL 2020  
Version 7: 08NOV2021  
Version 8: 30MAR2022 
  
Short Title:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced Urothelial 
Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page [ADDRESS_799605] OF ABBREVIATIONS  ......................................................................................................... 5  
PROTOCOL SIG NATURE  ......................................................................................................... 9  
STUDY SUMMARY.................................................................................................................... 10  
1 OBJECTIVES  ....................................................................................................................... 12  
1.1 Primary Objective and Endpoint .................................................................................... 12  
1.2 Secondary Objectives and Endpoints ............................................................................. 12  
1.3 Exploratory Objectives and Endpoints ........................................................................... 12  
2 BACKGROUND  .................................................................................................................. 12  
3 DRUG INFORMATION  ...................................................................................................... 15  
3.1 Cabozantinib................................................................................................................... 15  
3.2 Pembrolizumab ............................................................................................................... 21  
4 STUDY DESIGN .................................................................................................................. 23  
4.1 Description  ..................................................................................................................... 23  
4.2 Number of Patients ......................................................................................................... 23  
4.3 Number of Study Centers ............................................................................................... 23  
4.4 Study Duration  ............................................................................................................... 23  
4.5 Conditions for Terminating the Study ............................................................................ 23  
5 ELIGIBILITY CRITERIA .................................................................................................... 24  
5.1 Pre-Screening Eligibility for Patients Scheduled for Urothelial Diagnostic Procedure 
(biopsy or surgery) .................................................................................................................... 24  
5.2 Inclusion Criteria  ............................................................................................................ 25  
5.3 Exclusion Criteria  ........................................................................................................... 27  
6 TREATMENT PLAN  ........................................................................................................... 32  
6.1 Administration Schedule ................................................................................................ 32  
6.2 Cabozantinib................................................................................................................... 32  
6.3 Pembrolizumab (MK-3475) Treatment .......................................................................... 34  
6.4 Dose Calculation  ............................................................................................................ 36  
6.5 Preparation of Infusion Solution .................................................................................... 36  
6.6 Administration  ................................................................................................................ 37  
6.7 Accountability and Compliance ..................................................................................... 38  
6.8 Concomitant Medications and Therapi[INVESTIGATOR_014] ....................................................................... 39  
6.9 Duration of Therapy ....................................................................................................... 44  
7 TOXICITIES AND DOSEAGE MODIFICATION ............................................................. 45  
7.1 Dose Modifications and Guidelines for Adverse Event Management for Cabozantinib 45  
7.2 Dose modification and toxicity management guidelines for pembrolizumab................ 56  
7.3 Contraception ................................................................................................................. 60  
7.4 Supportive Care .............................................................................................................. 61  
8 STUDY CALENDAR  .......................................................................................................... 62  
9 STUDY PROCEDURES  ...................................................................................................... 64  
9.1 Pre-Screening  ................................................................................................................. 64  
9.2 Screening  ........................................................................................................................ 64  
9.3 On-Treatment Evaluations  ............................................................................................. 64  
Short Title:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced Urothelial 
Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page 4 of 82 9.4 End of Treatment Assessments (completed 28 days ± 14 days after completion of 
treatment  ................................................................................................................................... 65 
9.5 Follow -up Assessments  .................................................................................................. 66 
10 CRITERIA FOR EVALUATION AND ENDPOINT  .......................................................... 66 
10.1  Efficacy  ....................................................................................................................... 66 
10.2  Safety  .......................................................................................................................... 67 
11 STATISTICAL CONSIDERATIONS .................................................................................. 68 
11.1  Primary objective  ........................................................................................................ 68 
11.2  Secondary Objectives and Endpoints  ......................................................................... 68 
11.3  Exploratory Objectives and Endpoints  ....................................................................... 68 
12 REGISTRATION GUIDELINES  ......................................................................................... 69 
13 DATA SUBMISSION SCHEDULE  .................................................................................... 69 
14 SPECIAL INSTRUCTIONS  ................................................................................................ 69 
14.1  Corre lative Studies  ..................................................................................................... 69 
15 ETHICAL AND REGULATORY CONSIDERATIONS  .................................................... 71 
15.1  Informed consent  ........................................................................................................ 71 
15.2  Institutional Review  .................................................................................................... 71 
15.3  Data and Safety Monitoring Plan  ............................................................................... 71 
15.4  Adverse Events / Serious Adverse Events  .................................................................. 72 
15.5  SAE Reporting Requirements  .................................................................................... 74 
15.6  Reporting of Pregnancy  .............................................................................................. 75 
15.7  Medication Errors/Overdose  ....................................................................................... [ADDRESS_799606] Keepi[INVESTIGATOR_007]  .......................................................................................................... 76 
16 PUBLICATIONS OF DATA  ............................................................................................... 76 
17 BIBLIOGRAPHY  ................................................................................................................. 77 
APPENDIX A -  Cabozantinib Dosing Diary ............................................................................ 81 
APPENDIX B - Stool Sample Collection Questionnaire  .......................................................... 82 
  
Short Title:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced Urothelial 
Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page [ADDRESS_799607] OF ABBREVIATION S 
Abbreviation or 
Term1 Definition/Explanation  
AE Adverse event  
ALT  Alanine aminotransferase  
ANCOVA  Analysis of covariance  
ANOVA  Analysis of variance  
APTT  Activated partial thromboplastin time  
AST  Aspartate aminotransferase  
AV Atrioventricular  
β-HCG  Beta-human chorionic gonadotropin  
BID Twice daily  
BLQ  Below limit of quantification  
BMI  Body mass index  
BP Blood pressure  
BUN  Blood urea nitrogen  
Ca++ Calcium  
CBC  Complete blood count  
CFR  Code of Federal Regulations  
CHF  Congestive heart failure  
CI Confidence interval  
Cl- Chloride  
CL cr Creatinine clearance  
Cmax Maximum observed concentration  
Cmin Trough observed concentration  
CNS  Central nervous system  
CR Complete response  
CRF  Case report form  
CT Computed tomography  
Short Title:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced Urothelial 
Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page 6 of 82 Abbreviation or 
Term1 Definition/Explanation  
CTCAE  Common Toxicity Criteria for Adverse Events  
CV Coefficient of variation  
CYP  Cytochrome P450  
D/C Discontinue  
ECOG  Eastern Cooperative Oncology Group  
eCRF  Electronic case report form  
DLT  Dose Limiting Toxicity  
ECG  Electrocardiogram  
Eg Exempli gratia (for example)  
FACS  Fluorescence Activated Cell Sorting  
FDA  Food and Drug Administration  
FDG -PET Fluorodeoxyglucose (FDG) -positron emission tomography (PET)  
GCP  Good Clinical Practice  
GFR  Glomerular filtration rate  
GGT  Gamma glutamyl transferase  
GLP  Good laboratory practice  
HBsAg  Hepatitis B surface antigen  
HBV  Hepatitis B virus  
HCO 3- Bicarbonate  
HCV  Hepatitis C virus  
HIV Human immunodeficiency virus  
HR Heart rate  
hr Hour or hours  
IC50 Half maximal inhibitory concentration  
i.e. Id est (that is)  
IEC Independent ethics committee  
INR International normalized ratio  
Short Title:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced Urothelial 
Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page 7 of 82 Abbreviation or 
Term1 Definition/Explanation  
IRB Institutional review board  
IU International unit  
IV Intravenous, intravenously  
LDH  Lactate dehydrogenase  
LLQ  Lower limit of quantitation  
MedRA  Medical Dictionary for Drug Regulatory Activities  
MRI  Magnetic resonance imaging  
MRSD  Maximum recommended starting dose  
MTD  Maximum tolerated dose  
NOAEL  No-observed -adverse -effect level  
NOEL  No-observed -effect -level  
PD Pharmacodynamic(s)  
PFS Progression Free Survival  
PK Pharmacokinetic(s)  
PO Per os (administered by [CONTACT_1966])  
PR Partial response  
PT Prothrombin time  
PTT Partial thromboplastin time  
QC Quality control  
RBC  Red blood cell  
QD Once daily  
QTc QT interval corrected  
QTcF  QT interval corrected using Fredericia equation  
SAE  Serious adverse event  
SD Standard deviation or stable disease  
T1/2 Terminal elimination half -life 
T3 Triiodothyronine  
Short Title:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced Urothelial 
Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page 8 of 82 Abbreviation or 
Term1 Definition/Explanation  
T4 Thyroxine  
Tmax Time of maximum observed concentration  
TID Three times daily  
TSH  Thyroid -stimulating hormone  
ULN  Upper limit of normal  
ULQ  Upper limit of quantitation  
UV Ultraviolet  
WBC  White blood cell  
WOCBP  Women of childbearing potential  
WONCBP  Women of nonchildbearing potential  
1 All of these abbreviations may or may not be used in protocol.  
  
Short Title:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced Urothelial 
Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page [ADDRESS_799608] of the study, and the obligations o f 
confidentiality.  
This document is signed electronically through submission and approval by [CONTACT_079] [INVESTIGATOR_603827] (ERICA) system. F or this reason, the Principal 
Investigator [INVESTIGATOR_603828] a hand -written signature [CONTACT_603884].  
Instructions to multi- site Principal Investigators at locations other than Huntsman Cancer Institute: 
SIGN and DATE this  signature [CONTACT_603885]. Return the original, completed and 
signed, to the HCI Research Compliance Office. Retain a copy in the regulatory binder.  
 
 
 
____________________________________ _______________ 
Signature [CONTACT_789]    [CONTACT_1782] 
 
  ____________________________________ Principal Investigator [CONTACT_5627] (Print)  
   ____________________________________ Name [CONTACT_603886]:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced Urothelial 
Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page [ADDRESS_799609] -line therapy for 
cisplatin -ineligible advanced urothel ial carcinoma  
Short Title  CaboPembro  UC 
Protocol Number  IRB# 104688  
IND IND# [ADDRESS_799610] efficacy of 
combination pembrolizumab and cabozantinib . 
Study Duration  Accrual will take approximately 1 -2 years with 1 year of 
treatment and 6 months follow up. Total study duration 3- 4 
years.  
Study Centers  This study will be conducted at the Huntsman Cancer Institute 
and up to two additional cancer centers.  
Objectives  Primary Objective : Evaluate measurable disease overall 
response rate ( ORR).   
Secondary Objectives : Evaluation of progression -free survival 
(PFS) at 6 months (PFS6) , overall s urvival (OS) , and 
evaluation of toxicities of the combination .  
Number of Subjects  39 subjects  will be enrolled to ensure 35 evaluable patients  
Diagnosis and Main 
Eligibility Criteria  Cisplatin -ineligible urothelial carcinoma  
Key Inclusion Criteria:  
• Histologically proven transitional cell or urothelial 
carcinoma (UC).  
• Metastat ic (any N+ or M1) or locally advanced , 
unresectable (T4bN0) disease . 
• Measurable disease is required as determined by [CONTACT_393]  
v1.1. 
• Cisplatin -ineligibility based on ≥1 of the following:  
o Estimated CrCl of between ≥ 40 and <60 ml/min (CG 
formula)  
o ECOG PS ≥2 
o Hearing loss  
o Baseline neuropathy  
o Patient refusal  
Key Exclusion Criteria:  
• Prior chemotherapy for metastatic/ advanced urothelial 
carcinoma.  
• Prior chemotherapy treatment  for localized  urothelial 
carcinoma that has been completed less than  6 months  
before registration . 
Short Title:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced Urothelial 
Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page 11 of 82 • Small -cell or sarcomatoid component in histology . 
Study Product, Dose, 
Route, Regimen  Pembrolizumab 200mg IV q 3 weeks with cabozantinib  
administered 40mg oral ly, with dose reductions to 20 mg  daily . 
Subsequent dose reduction to 20 m g every other day to 
improve tolerability is allowed.  
Duration of 
administration  Patients will receive therapy until treatment discontinuation 
criteria is met  or until 12 months  from start of therapy  
Reference therapy  Study t reatment will be compared to pembrolizumab as single 
agent .  
Statistical 
Methodology  A 95% one -sided exact binomial confidence interval (Clopper -
Pearson) will be calculated for ORR. With 35 evaluable 
subjects the lower bound of the 95% confidence interval will extend no more than 26%  from the observed proportion. If 
there are 17 or more objective responses in 35 patients the confidence interval will exclude 32%. Secondary analyses will include an association of risk group (based on performance  
status and visceral metastasis) with PFS . Stratified Kaplan -
Meier methodology will be used to associate risk group (based 
on performance status and visceral metastasis) with PFS.  
   
Short Title:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced Urothelial 
Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page 12 of 82 1 OBJECTIVES  
1.1 Primary Objective and Endpoint  
To evaluate measurable disease overall response rate (ORR).  
Endpoint : Subjects will be evaluated by [CONTACT_603861] v1.1 criteria for the duration of treatment.  
1.2 Secondary Objectives and Endpoint s 
 To evaluate progression -free survival (PFS) at 6 months (PFS6).  
Endpoint : Subjects w ill be evaluated by [CONTACT_603861] v1.1 criteria for the duration of treatment . 
 To evaluate Overall Survival (OS) . 
Endpoint : Subjects will be evaluated  using Kaplan- Meier estimation  for survival for up to 6 
months after discontinuation of study treatment ; patients surviving longer than 6 months  will 
be censored . 
 To evaluate toxicities associate with the combination treatment.  
Endpoint : Adverse events will be collected beginning with study treatment and tabulated 
according to drug attribution. 
1.3 Exploratory Objective s and Endpoints  
 To evaluate molecular markers for pharmacodynamic pathways associated with 
response.  
Endpoint s: Blood, t issue , and stool  samples will be collected at various time points to 
measure molecular markers to correlate with response to develop a panel predictive of response which will be validated in future studies. Once the model is determined, statistical methods will be determined. 
 To evaluate ORR and PFS6 using immune specific disease assessment criteria  
Endpoint: Subjects will be evaluated by [CONTACT_603862] . 
[ADDRESS_799611] -line therapy for urothelial carcinoma (UC) is cisplatin based 
chemotherapy. However, many patients diagnosed with UC are not eligible for cisplatin due to age, frailty or other comorbid conditions. In a retrospective analysis of 299 patient s presenting in 
a community -based cancer center system with stage 4 disease, the regimens administered were 
cisplatin based in 107 patients (35.9%), carboplatin based in 81 (27.2%), and non- platinum based 
in 25 (8.4%).
1 Notably, no chemotherapy was adminis tered in 71 (23.8%) patients. Cisplatin 
administration was more common in patients aged ≤70 years (62/150 [41.3%]) as opposed to >70 years (45/148 [30.4%]) (P = 0.05).  
Short Title:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced Urothelial 
Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page 13 of 82 In another retrospective study of 1031 patients aged ≥66 years presenting with advanced bladder 
cancer in the SEER -Medicare linked database, among patients receiving chemotherapy, 
carboplatin accounted for 50.6%, cisplatin for 39.7% and other agents for 9.8%.2 A relatively 
large proportion of patients did not receive chemotherapy in this Medicare database (48.4%), again highlighting the difficulties of administering aggressive chemotherapy in this population. The reasons for non- administration of cisplatin were not available in both of these studies, 
although it may be postulated that the pre sence of renal dysfunction, poor performance status, 
elderly age and comorbidities likely are responsible as these are frequent exclusion criteria for previously reported large phase III clinical trials of cisplatin based chemotherapy for UC.  
Carboplatin i s often substituted for cisplatin in cisplatin -ineligible patients, but is associated with 
inferior response rates, especially CR rates, which suggests the lack of potential cures. In a meta -
analysis of randomized phase II trials, cisplatin -based chemother apy was associated with a 
significantly higher likelihood of achieving a CR (relative risk {RR} = 3.54; 95% confidence interval {CI} 1.48 -8.49; P = 0.005) and ORR (RR = 1.34; 95% CI 1.04- 1.71; P = 0.02) compared 
to carboplatin- based chemotherapy.
3 Clearly,  other tolerable and high- effective therapi[INVESTIGATOR_603829]- ineligible invasive urothelial carcinoma.  
In a previously reported study,4 prognostic markers for poor clinical outcomes associated with 
disease progression were studied. The authors demonstrated that expression of Met was 
positively associated with histologic grade, stage classification, tumor size, and nodular tumor 
growth (P <.05, respectively) in urothelial carcinoma. Factors that predicted disease p rogression 
were tumor stage, Met status, and TP53 accumulation (P <.05, respectively). Indicators for poor long-term survival were invasive cancer, multiple tumors, and Met overexpression (P =0.0006, 
0.01 and 0.04, respectively). The authors concluded that  the c- met proto -oncogene plays a more 
important role in the progression of bladder carcinogenesis. Evaluation of Met expression could identify a subset of bladder cancer patients who may benefit from molecularly targeted therapy.  
In a recent report, a pos itive association of Axl or platelet- derived growth factor receptor -alpha 
(PDGFR -α) with c -Met expression was demonstrated through preclinical models of disease.
5 The 
transactivation of c -Met on Axl or PDGFR -α in vitro was through a ras - and Src- independent 
activation of mitogen -activated protein kinase/extracellular signal -regulated kinase (MEK/ERK) 
pathway. In human bladder cancer, co- expression of these RTKs was associated with poor 
patient survival (p < 0.05), and overexpression of c -Met/Axl/PDGFR -α or c-Met alone showed 
the most significant correlation with poor survival (p < 0.01). Thus, in addition to c -Met, the 
cross -talk with Axl and/or PDGFR -α also contributes to the progression of human bladder 
cancer.  
Finally, recent data6 suggest significant act ivity for Met inhibition in bladder cancer. PF -2341066 
(crizotinib), a small, orally available, highly specific Met- inhibitor was evaluated in an 
orthotopic xenograft model of bladder transitional cell carcinoma (TCC). Animals were treated with intra peritoneal PF -2341066 after positive detection of bladder tumor primary and/or 
metastatic disease. Fluorescence imaging (Xenogen IVIS) of mice was performed weekly. Mice were euthanized [ADDRESS_799612] a small orally available 
Short Title:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced Urothelial 
Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page 14 of 82 Met-selective inhibitor in an orthotopic, HGF -driven model of human bladder cancer, supporting 
its potential use in patients with bladder cancer.  
In vitro biochemical and/or cellular assays have shown that cabozantinib inhi bits the tyrosine 
kinase activity of RET, MET, VEGFR -1, -2 and -3, KIT, TRKB, FLT -3, AXL, and TIE -2. This 
suggests that cabozantinib may be effective in urothelial carcinoma.  This concept is currently 
being studie d in an ongoing clinical trial evaluating the efficacy of single agent cabozantinib 
([STUDY_ID_REMOVED]), with final results expected soon. Preliminary  results suggest clinical activity 
with single agent cabozantinib with objective radiographic responses seen.  
Previously, immune -based treatments have demonstrated significant clinical benefit as single 
agent therapi[INVESTIGATOR_603830]. To date, many different immunotherapi[INVESTIGATOR_603831] -1 
antagonists (pembrolizumab, nivolumab) and PD -L1 antagonists (atezolizumab, avelumab, 
durvalumab). In the second- line pembrolizumab trial for patients with UC (KEYNOTE -045)7, 
542 patients were randomized to pembrolizumab or the treating physician’s  choice of 
chemotherapy (vinflunine, docetaxel or paclitaxel) with significant clinical benefit demonstrated 
in the pembr olizumab arm. The overall survival was improved at 10.3 months versus 7.4 months 
for pembrolizumab versus chemotherapy respectively (HR for death 0.73; 95% CI 0.59—0.91;  P 
= 0.002). It was also better tolerated with decreased grade 3 -5 adverse events (15.0% versus 
49.4% respectively). Pembrolizumab is now one standard- of-care option that is  FDA approved 
for UC  in the second -line setting . Similarly, durvalumab8, atezolizumab ,[ADDRESS_799613] -line setting. Immunotherapy for urothelial carcinoma is 
clearly effective, active therapy in urothelial carcinoma. However, the primary challenge with these therapi[INVESTIGATOR_603832]. In the KEYNOTE -045 clinical trial of second -
line pembrolizumab for i nstance, there was a low 21.1% response rate for pembrolizumab 
compared to 11.4% with chemotherapy. Robust responses are frequently observed with immunotherapy, but unfortunately only a relatively few number of patients experience a response to this type of treatment .  
Using both cabozantinib plus pembrolizumab in cisplatin- ineligible UC is attractive as this may 
be a well -tolerated and synergistically active combinat ion. VEGFR therapy appears to modulate 
the immune system, suggesting possible clinical benefit for this combination. In mouse models, axitinib (another multi- targeted kinase inhibitor similar to cabozantinib) demonstrated a 
significant increase in the numb er of tumor infiltrating lymphocytes and altered the 
microenvironment from a suppressive to a stimulatory environment relative to vehicle controls.
13 
Another study analyzing archival tissue from patients with metastatic renal cell carcinoma 
demonstrated a positive relationship between tumor -infiltrating lymphocytes and VEGF gene 
expression (r = - 0.18; P = 0.089), suggesting that the VEGF pathway partially regulates the 
immune effect in kidney cancer. This theory has been tested in a pi[INVESTIGATOR_603833].14 Patients were treated with 1 cycle of bevacizumab (a VEGF antagonist) prior to 
treatment with the combination of atezolizumab (a PD -L1 antagonist) and bevacizumab. Patients 
underwent biopsies at baseline, after the lead -in phase with bevaci zumab and after two cycles of 
the combination therapy. The tumor tissue demonstrated an increase in gene signatures associated with Th1, CD8, and natural killer cell activity after treatment at all times in the study including after the bevacizumab -only pe riod. This strongly suggests that the combination of 
VEGFR TKI and immunotherapy with PD -L1 therapy will be effective and safe in patients with 
Short Title:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced Urothelial 
Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page [ADDRESS_799614] importantly, the combination of axitinib plus 
avelumab was recentl y reported in a phase IB clinical trial of 55 patients with metastatic renal 
cancer.15 This combination appears to be relatively well tolerated with an incidence of grade 3 -5 
toxicities in 52% (axitinib related) and 20.0% (avelumab related) of patients. The confirmed overall response rate was 54.5% (95% CI 40.6—68.0) with [ADDRESS_799615]- line treatment. A lso we hypothesize that t his combination 
will demonstrate significant additive or synergistic activity  resultin g in a 20% increase in 
response  in this disease compared to historic benchmarks for progression- free survival.  
3 DRUG INFORMATION 
3.1 Cabozantinib   
 Description  
Cabozantinib is the  (S)-malate salt of cabozantinib, a kinase inhibitor. C abozantinib ( S)-
malate  is described chemically  as N-(4-(6, 7- dimethoxyquinolin- 4-yloxy) phenyl) -N’-(4- 
fluorophenyl) cyclopropane -1, 1-dicarboxamide, (2S) -hydroxybutanedi oate.  The molecular 
formula is C28H24FN 3O5·C4H6O5 and the molecular weight  is 635.6 Daltons  as malate salt. 
Cabozantinib  (S)-malate  salt is a white to off- white solid that is practically  insoluble  in 
aqueous  media.  
Cabozantinib  tablets  are supplied  as film -coated  tablets containing  20 mg  of cabozantinib, 
which  is equivalent  to 25 mg  of cabozantinib (S)-malate . Cabozantinib  also contains the  
following  inactive  ingredients:  microcrystalline cellulose,  lactose anhydrous, 
hydroxypropyl  cellulose,  croscarmellose sodium, colloidal  silicon  dioxide,  and magnesium  
stearate.  
The film  coating  contains hypromellose,  titanium dioxide, triacetin,  and iron oxide  yellow.  
 Pharmacology  
Mechanism of Action  
In vitro  biochemical  and/or  cellular  assays  have shown that  cabozantinib  inhibits the  
tyrosine  kinase activity  of MET,  VEGFR -1, -[ADDRESS_799616] of orally administered cabozantinib  140 mg on QTc interval was evaluated in a 
randomized, double -blinded, plac ebo-controlled study in patients with MTC. A mean 
increase in QTcF of 10 - 15 ms was observed at 4 weeks after initiating cabozantinib . A 
concentration -QTc relationship could not be definitively established. Changes in cardiac 
Short Title:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced Urothelial 
Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page [ADDRESS_799617] form morphology or new rhythms were not observed. No cabozantinib- treated 
patients had a QTcF > 500 ms. Details can be found in the Investigator’s Brochure 
The effect of orally administered cabozantinib 140 mg qd on corrected QT interval (QTc) 
was evaluated in a placebo -controlled study in subjects with medullary thyroid cancer 
(evaluable subjects: cabozantinib arm, 209; placebo arm, 107). A mean increase in Fridericia’s correction of QT interval (QTcF) of [ADDRESS_799618] form morphology or new rhythms were not observed. No cabozantinib-treated subjects in this study had a QTcF > 500 ms. Review of the l arger safety database (~[ADDRESS_799619]- marketing experience) confirmed the absence of safety concerns associated with 
QT prolongation. There were no events of torsades de pointes reported. 
Clinical Phar macokinetics  
Pharmacokinetics  
A population PK analysis was conducted in subjects with RCC who received repeated oral 
daily cabozantinib tablet dosing at 60 mg (with protocol -permitted dose reductions to 40 
mg and 20 mg) combined with healthy subjects who r eceived a single oral cabozantinib 
tablet dose of 20, 40, or [ADDRESS_799620], the 
predicted terminal plasma half -life of cabozantinib was approximately 99 h; the terminal 
phase volume of distribution (Vz) was approximately 319 L; and the CL/F at steady- state 
was estimated to be approximately 2.2 L/h. Female gender and Asian race were significant 
covariates on CL/F, and while the attributes were statistically significant, they were not deemed clinically meaningful  given the magnitude of the effects.  
Absorption and Distribution 
Following oral administration of cabozantinib , median time to peak cabozantinib plasma 
concentrations (Tmax) ranged from [ADDRESS_799621]- dose. Repeat daily dosing of 
cabozantinib  at 140 mg for 19 days resulted in 4- to 5 -fold mean cabozantinib accumulation 
(based on AUC) compared to a single dose administration; steady state was achieved by [CONTACT_2006] 15. Cabozantinib  is highly protein bound in human plasma (99.7%). A high- fat meal 
increased Cmax and AUC values by 41% and 57%, respectively relative to fasted conditions in healthy subjects administered a single 140 mg oral cabozantinib  dose.  
Metabolism and Elimination  
Cabozantinib  is a substrate of CYP3A4 in vitro. Inhibition of CYP3A4 reduced the 
formation of the XL184 N-oxide metabolite by >80%. Inhibition of CYP2C9 had a 
minimal effect on cabozantinib  metabolite formation (i.e., a <20% reduction). Inhibition of 
CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C19, CYP2D6 and CYP2E1 had no effect on cabozantinib  metabolite formation. Within a 48 -day collection period after a single dose 
of 
14C- cabozantinib  in healthy subjects, approximately 81% of the total administered 
radioactivity was recovered with 54% in feces and 27% in urine. 
Short Title:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced Urothelial 
Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page 17 of 82 Specific Populations  
Renal Impairment  
Cabozantinib should be used with caution in subjects with mild or moderate renal 
impairment. No formal pharmacokinetic study of cabozantinib  has been conducted in 
patients with renal impairment. The results of a population pharmacokinetic analys is 
suggested that mild to moderate renal impairment (creatinine clearance value <30 mL/min) 
does not have a clinically relevant effect on the clearance of cabozantinib . 
Hepatic Impairment  
Cabozantinib should be used with caution and dose reductions may be  warranted in 
subjects with mild or moderate hepatic impairment, and clinical monitoring is recommended for these subjects. Cabozantinib is not recommended for use in subjects with severe hepatic impairment as safety and efficacy have not been established in this population 
The pharmacokinetics of cabozantinib  has not been studied in patients with hepatic 
impairment .  
Pediatric p opulation: This study will not enroll pediatric patients . 
Effects of Age, Gender and Race: A population PK analysis did not identi fy clinically 
relevant differences in clearance of cabozantinib between females and males or between 
Whites (89%) and non- Whites (11%). C abozantinib  pharmacokinetics was not affected by 
[CONTACT_654] (20 -86 years).  
Drug Interactions  
CYP Enzyme Inhibition and Inducti on: cabozantinib is a noncompetitive inhibitor of 
CYP2C8 (Kiapp = 4.6 μM), a mixed- type inhibitor of both CYP2C9 (Kiapp = 10.4 μM) 
and CYP2C19 (Kiapp = 28.8 μM), and a weak competitive inhibitor of CYP3A4 (estimated 
Kiapp = 282 μM) in human liver microsoma l (HLM) preparations. IC50 values >20 µ M 
were observed for CYP1A2, CYP2D6, and CYP3A4 isozymes in both recombinant and 
HLM assay systems. Cabozantinib  is an inducer of CYP1A1 mRNA in human hepatocyte 
incubations (i.e., 75-100% of CYP1A1 positive control _ naphthoflavone induction), but not of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19 or CYP3A4 mRNA or isozyme -
associated enzyme activities. Cabozantinib  at stead y-state plasma concentrations ( 100 
mg/day daily for a minimum of 21 days) showed no effect on single-dose rosiglitazone (a CYP2C8 substrate) plasma exposure (Cmax and AUC) in patients with solid tumors.  
P-glycoprotein i nhibition: cabozantinib is an inhibitor (IC50 = 7.0 µ M), but not a substrate, 
of P-gp transport activities in a bi -directional assay syst em using MDCK -MDR1 cells. 
Therefore, cabozantinib may have the potential to increase plasma concentrations of co -
administered substrates of P -gp. Details can be found in the Investigator’s Brochure. 
Short Title:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced Urothelial 
Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page [ADDRESS_799622] not been conducted. 
cabozantinib  was not mutagenic in vitro in the bacterial reverse mutation (Ames) assay and 
was not clastogenic in both the in vitro cytoge netic assay using human lymphocytes or in 
the in vivo mouse micronucleus assay. Based on nonclinical findings, male and female 
fertility may be impaired by [CONTACT_603863] . In a fertility study in which 
cabozantinib  was administered to male and  female rats at doses of 1, 2.5, and 5 mg/kg/day, 
male fertility was significantly compromised at doses equal to or greater than 2.5 mg/kg/day (approximately equal to the human exposure by [CONTACT_603864]), with a decrease in sperm counts and r eproductive organ weights. In females, fertility 
was significantly reduced at doses equal to or greater than 1 mg/kg/day (approximately 50% of the human exposure by [CONTACT_603864]) with a significant decrease in the number of live embryos and a significant increase in pre-  and post -implantation  
losses. Observations of effects on reproductive tract tissues in general toxicology studies were supportive of effects noted in the dedicated fertility study and included hypospermia and absence of corpo ra lutea in male and female dogs in a 6 -month repeat dose study at 
exposures equal to 6% and 3%, respectively, the human exposure by [CONTACT_603865]. In addition, female rats administered 5 mg/kg/day for 14 days 
(approximately equal to the huma n exposure by [CONTACT_603864]) exhibited 
ovarian necrosis. Details can be found in the Investigator’s Brochure.  
 Clinical Experience 
Adverse Events  
The most frequent AEs experienced by ≥ 20% of subjects treated with cabozantinib in descending or der of frequency were diarrhea, fatigue, decreased appetite, nausea, weight 
decreased,  palmar plantar e rythrodysesthesia syndrome  (PPES) , vomiting, constipation, 
hypertension, dysgeusia, dysphonia, asthenia, and dyspnea. For a full description of the safety profile of cabozantinib, refer to the most recent cabozantinib Investigator’s Brochure.  
Other medically important but less frequent AE s including arterial thrombotic AEs (e .g., 
transient ischemic attack [TIA], and myocardial infarction [MI]) and venous thrombotic AEs (e.g., deep vein thrombosis [DVT] and pulmonary embolism), severe hemorrhagic events, 
proteinuria, wound healing complicat ions, gastrointestinal (GI) perforation, abscesses 
including intra -abdominal and pelvic abscess, GI and non- GI fistula formation, 
osteonecrosis, and reversible posterior leukoencephalopathy syndrome (RPLS).  
Adverse events associated with laboratory abnorma lities experienced by ≥ 5% of subjects 
treated with cabozantinib in descending order of frequency were anemia, AST increased, ALT increased, hypothyroidism, hypokalemia, hypomagnesemia, thrombocytopenia, hypocalcemia, hypophosphatemia, lactate dehydrogenas e (LDH) increased, lipase increased, 
neutropenia, hyponatremia, ALP increased, leukopenia, and hyperglycemia. 
Adverse events may occur within the first few weeks in the course of treatment with 
cabozantinib, as cabozantinib is expected to reach steady state exposure at approximately [ADDRESS_799623] an early onset include hy pocalcemia, 
Short Title:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced Urothelial 
Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page [ADDRESS_799624] range of clinical anti -tumor activity in early Phase 1 
and Phase 2 studies in Medullary Thyroid Carcinoma (MTC) and several other tumor types. In a randomized discontinuation trial (RDT) XL184- 203, the following di sease control rates 
(DCR = complete response [CR] + partial response [PR] + stable disease [SD]) at Week 12 were observed : non- small cell lung cancer (NSCLC), 38%; breast cancer, 48%; melanoma, 
46%; ovarian cancer, 53%; HCC, 66%; and CRPC, 66%. Observations of clinical activity have included decrease of soft tissue tumor lesions including visceral metastases, effects on metastatic lesions on bone scan (partial or complete bone scan resolution), reduction in serum markers of bone resorption and formation, re duction in circulating tumor cells (CTCs; 
subjects with prostate cancer), increases in hemoglobin, and improvements in bone pain and reductions in narcotic use in subjects with bone metastases. In the placebo -controlled Phase 3 
study XL184- 301 in 330 MTC s ubjects, a significant increase in median PFS was seen in the 
cabozantinib arm compared with placebo (11.2 vs 4.0 months; hazard ratio [HR] =0.28; 95 CIs: 0.19, 0.40)  with durable response (median of 14.6 months). An unplanned 
administrative analysis of ov erall survival (OS) performed at the request of the FDA with a 
data cut -off of 15 June 2012 (75% of required deaths) showed a trend for improved duration 
of OS in the cabozantinib arm compared with placebo (26.0 months vs 20.3 months; HR = 0.83; 95% CI: 0.60, 1.14).  
In the Phase [ADDRESS_799625] clinical activity in men 
with CRPC. During the RDT phase, the majority of CRPC subjects with bone metastases and elevated total alkaline phosphatase (t -ALP) levels at baseline show ed reductions in t -ALP 
16. 
These effects were independent of prior or concomitant bisphosphonate treatment. Subjects achieved a bone scan response (BSR) in both the 100 mg and 40 mg assigned NRE dose cohorts (73% and 45%, respectively). In addition, cabozantinib  treatment has shown effects 
on bone metastases (by  [CONTACT_20420] [CT], or bone scan) in five tumor types, 
including CRPC, breast cancer, DTC (papi[INVESTIGATOR_1396]), melanoma, and RCC. These effects include partial or complete bone scan resolution associa ted with reduction in circulating markers of 
bone resorption and formation, reduction in CTCs (CRPC), increases in hemoglobin, 
improvements in bone pain, and reductions in narcotic use. 
The preliminary analysis of an ongoing phase II study with cabozantini b in patients with 
heavily pretreated relapsed or refractory advanced UC revealed promising clinical activity 
([STUDY_ID_REMOVED]) 
17, 18. Preliminarily, responses have been observed in 13% of 26 patients and 
associated with low peripheral blood regulatory T cell s (Tregs). Moreover, cabozantinib 
decreased Tregs and increased PD -1 expression in Tregs, suggesting a potential role for 
combination or sequencing with immunotherapy.  
Short Title:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced Urothelial 
Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page 20 of 82 CTEP Study: A Phase II Study of Cabozantinib (XL184) in Subjects w ith 
Advanced/Metastati c Urothelial Carcinoma  
A total of 67 eligible subjects with diagnoses of progressive metastatic carcinoma of the 
bladder, urethra, ureter, or renal pelvis were enrolled in three cohorts: Cohort 1 (n=50), metastatic UC; Cohort 2 (n=6), bone only metastatic UC; Cohort 3 ( n=11), non- UC (rare 
histologies ).
26 Subjects were treated with 60 mg cabozantinib orally qd. 
In Cohort 1, ORR for 42 evaluable subjects was determined to be 19.1% with 7 PRs and 1 CR. Median PFS for these subjects was 3.7 months (95% CI: 3.1, 6.5), and median OS was 8.0 months (95% CI: 5.2, 10.3) with 27.2% of subjects still alive 12 months after starting study treatment. Median OS among responders (n=8) was 21.5 months (95% CI: 7.3, 36.0). The median PFS for evaluable subjects with bone-only disease (Cohort 2, n=5) was 5.3 months (95% CI: 1.8, 8.3), and median OS was 9.3 months (95% CI: 3.6, 12.5). For evaluable subjects with non- urothelial rare histologies (Cohort 3, n=10), median PFS was 2.9 
months (95% CI: 1.8, 3.7), and median OS was 4.6 months (95% CI: 2.6, 8.0). 
Across all cohorts (n=67), the most frequently reported cabozantinib- related AEs were 
anemia (94%), PPES (83%), fatigue (69%), diarrhea (67%), AST increased (59%), platelet 
count decreased (58%), hypoalbuminemia (55%), hypophospha temia (49%), creatinine 
increased (38%), nausea (36%), and hypothyroidism (40%); most of these AEs were Grade [ADDRESS_799626] frequent Grade 3 AEs related to cabozantinib were fatigue (9%), hypertension 
(7%), hypophosphatemia (6%), AST increased (4%), pla telet count decreased (4%), diarrhea 
(3%), abdominal pain (3%), hyponatremia (3%), lymphocyte count decreased (3%), and proteinuria (3%). Grade 4 AEs were reported for hypomagnesemia (3%) and lipase increased (1%); no Grade 3 events were reported for eithe r of these terms.  
CTEP Study: A Phase I/Expansion Study of Cabozantinib plus Nivolumab Alone or With 
Ipi[INVESTIGATOR_603834] 1 clinical trial in subjects with refractory  metastatic UC and other 
genitourinary tumors, cabozantinib has been evaluated in combination with nivolumab, a monoclonal antibody to PD-1, and in combination with both nivolumab and ipi[INVESTIGATOR_125], a monoclonal antibody to CTLA- 4 (CaboNivo and CaboNivoIpi, r espectively).
27 Forty -three 
(43) of 48 subjects enrolled were assessed for tumor response at the time of analysis (CaboNivo 26 subjects; CaboNivoIpi: 17 subjects). The ORR was 38% in the CaboNivo cohort (8 PRs and 2 CRs) and 18% in the CaboNivoIpi [CONTACT_9084] (2 PRs and 1 CR); among the 16 evaluable metastatic UC subjects across both cohorts, the ORR was 38% (4 PRs and 2 CRs).  
CaboNivo and CaboNivoIpi [INVESTIGATOR_603835]-tolerated among all enrolled subjects, and no DLTs were reported. Grade 3 AEs among subjects in the CaboNivo cohort irrespective of relationship to study treatment comprised neutropenia (n=5), hypophosphatemia (n=4), hypertension (n=3), dehydration, diarrhea, fatigue, lipase increased (each n=2), amylase increased, anemia, aseptic meningitis, hyperthyroidi sm, hyponatremia, proteinuria, 
thrombocytopenia, thromboembolic event, vomiting (each n=1); Grade 3 AEs among subjects in the CaboNivoIpi [INVESTIGATOR_603836], hypophosphatemia (each n=3), fatigue, hyponatremia, lipase increased, nausea (each n=2) , alanine aminotransferase 
Short Title:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced Urothelial 
Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page 21 of 82 increased, anorexia, colitis, rash (each n=1). Grade 4 AEs in the CaboNivo cohort comprised 
lipase increased (n=2) and thrombocytopenia (n=1); there was one Grade 4 AE of lipase increased in the CaboNivoIpi [CONTACT_9084]. There were no Grade 5 AEs.   
More details regarding the efficacy of cabozantinib can be found in the Investigator ’s 
Brochure.  
 Translational Medicine  
In preclinical studies, cabozantinib has shown potent anti -angiogenic, tumor growth 
inhibition, and tumor regression effec ts in vivo. In addition, cabozantinib blocked metastasis 
and improved overall survival in the transgenic RIP -Tag2 mouse model of pancreatic 
neuroendocrine cancer 19. In human prostate and breast xenograft models, cabozantinib 
blocked osteoblastic and osteolytic progression of tumors in bone. C abozantinib inhibited 
progression of multiple prostate cancer cell lines in bone metastatic and soft tissue murine models of prostate cancer and exerted a dose -dependent biphasic effect on osteoblast activity 
and inhibitory effect on  osteoclast production in vitro 
20 Oral administration of cabozantinib 
resulted in blockade of MET phosphorylation in human lung tumor xenografts grown in nude mice, blockade of MET phosphorylation in livers of mice, and blockade of VEGFR2 phosphorylation in mouse lung tissue. For both targets, the duration of action for cabozantinib was sustained, with > 50% inhibition observed for > [ADDRESS_799627] -dose at a 
single dose le vel of 100 mg/kg 
21 Anti -tumor effects of cabozantinib, were also examin ed in 
cultured HCC cells as well as in vivo models. In cultured HCC cells that are refractory to sorafenib and expressed p- MET (phosphorylated -MET), the cabozantinib inhibited the 
activity of MET and its downstream effectors, leading to G1 phase arrest wit h relatively 
more profound efficacy in p- MET- positive HCC xenografts 
22. Details can be found in the 
Investigator’s Brochure.  
3.[ADDRESS_799628] recent Investigator’s Brochure (IB) for detailed background information on 
MK-3475 (Pembrolizumab) . 
 Pharmaceutical and Therapeutic Background 
The importance of intact immune surveillance in controlling outgrowth of neoplastic transformation has been known for decades . Accumulating evidence shows a correlation 
between tumor -infiltrating lymphocytes (TILs) in cancer tissue and favorable prognosis in 
various malignancies . In particular, the presence of CD8+ T -cells and the ratio of CD8+ 
effector T -cells / FoxP3+ regulatory T -cells seems to correlate with improved prognosis and 
long-term survival in man y solid tumors. 
The PD -[ADDRESS_799629] hijacked by [CONTACT_55548] . The normal function of PD -1, expressed on the cell surface of activated T -
cells under healthy conditions, is to down- modulate unwanted or  excessive immune 
responses, including autoimmune reactions . PD-1 (encoded by [CONTACT_13228]1) is an Ig 
superfamily member related to CD28 and CTLA -4 which has been shown to negatively 
regulate antigen receptor signaling upon engagement of its ligands (PD -L1 and/or PD -L2). 
The structure of murine PD -1 has been resolved. PD-1 and family members are type I 
Short Title:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced Urothelial 
Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page 22 of 82 transmembrane glycoproteins containing an Ig Variable -type (V -type) domain responsible 
for ligand binding and a cytoplasmic tail which is responsible for the binding of signaling 
molecules . The cytoplasmic tail of PD -1 contains 2 tyrosine -based signaling motifs, an 
immunoreceptor tyrosine -based inhibition motif (ITIM) and an immunoreceptor tyrosine -
based switch motif (ITSM) . Following T -cell stimulation, PD -[ADDRESS_799630] from that of CTLA -4 as both molecules 
regulate an overlappi[INVESTIGATOR_77971] . PD-1 was shown to be expressed on 
activated lymphocytes including peripheral CD 4+ and CD8+ T -cells, B -cells, T regs and 
Natural Killer cells . Expression has also been shown during thymic development on CD4-
CD8 - (double negative) T -cells as well as subsets of macrophages and dendritic cells . The 
ligands for PD -1 (PD -L1 and PD -L2) are constitutively ex pressed or can be induced in a 
variety of cell types, including non- hematopoietic tissues as well as in various tumors . Both 
ligands are type I transmembrane receptors containing both IgV - and IgC -like domains in the 
extracellular region and contain short cytoplasmic regions with no known signaling motifs . 
Binding of either PD -[ADDRESS_799631] 
notably on vascular endo thelium, whereas PD -L2 protein is only detectably expressed on 
antigen -presenting cells found in lymphoid tissue or chronic inflammatory environments . 
PD-L2 is thought to control immune T -cell activation in lymphoid organs, whereas PD -L1 
serves to dampen unwarranted T -cell function in peripheral tissues . Although healthy organs 
express little (if any) PD -L1, a variety of cancers were demonstrated to express abundant 
levels of this T -cell inhibitor . This suggests that the PD -1/PD -L1 pathway plays a critical role 
in tumor immune evasion and should be considered as an attractive target for therapeutic intervention. 
Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of 
the IgG4/kappa isotype designed to directly block the interact ion between PD -1 and its 
ligands, PD -L1 and PD -L2. Keytruda
TM (pembrolizumab) has recently been approved in the 
United Stated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipi[INVESTIGATOR_77972], if BRAF V [ADDRESS_799632] recent Investigator’s Brochure for Preclinical and Clinical data.  
 Rationale for Dose Selection/Regimen/Modification  
PK data analysis of MK -3475 administered Q3W showed slow systemic clearance, limited 
volume of distribution, and a long half -life (refer to IB). Pharmacodynamic data (IL -2 release 
assay) suggested that peripheral target engagement is durable (>21 days) . This early PK and 
pharmacodynamic data provides  scientific rationale for testing a Q3W dosing schedule . This 
clinical trial uses the FDA approved dose and schedule for treatment of metastatic urothelial carcinoma.  
Short Title:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced Urothelial 
Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page 23 of 82 4 STUDY DESIGN 
4.1 Description  
This is an open label, non- randomized phase 2 study  of the comb ination of pembrolizumab 
and c abozantinib to assess overall response rate (ORR), progression free survival at 6 months 
(PFS6), and overall survival (OS) i n patients with metastatic urothelial carcinoma (UC) 
ineligible for c isplatin . Cabozantinib is administered at [ADDRESS_799633] 6 patients enroll and receive treatment. During this stage, the decision to continue enrollment will be made by [CONTACT_603866] C ommittee (DSMC). When all [ADDRESS_799634] dose of pembrolizumab and cabozantinib, a ll available safety data 
will b e considered in a decision to continue enrollment. Therapy continues until progression 
or intolerable toxicities.  Study treatment may  continue beyond initial radiographic or clinical 
disease progression as long as the patient is deriving clinical benefit f rom the treatment, as 
assessed by [CONTACT_093]. Patients removed from therapy without evidence of progression 
will undergo radiological examination every 12 weeks or earlier if clinically warranted.  
4.2 Number of Patients  
A total of up to 39 subjects w ill be enrolled with the objective of having a minimum of 35 
evaluable subjects for the primary objective.  
4.3 Number of Study Centers  
This is a multisite study to be conducted at Huntsman Cancer Institute at the University of 
Utah, Salt Lake City, Utah. Up to two additional sites may be included.  
4.4 Study Duration  
We anticipate up to 2 years to complete enrollment followed by 1 year of tre atment and 5 
months follow up. Total duration of the trial will be 3 -to-4 years.  
4.5 Conditions for Terminating the Study  
At any time , the study may be terminated by [CONTACT_603867].   
Short Title:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced Urothelial 
Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page 24 of 82 5 ELIGIBILITY CRITERIA  
5.1 Pre-Screening E ligibility  for Patients Scheduled for Urothelial  Diagnostic 
Procedure (biopsy or surgery)  
This eligibility  checklist is used to determine a subject’s eligibility for pre -screening 
correlative tissue collection . It must be filed in the subject’s  research chart with the enrolling 
investigator’s signature.  
Patient No. ______________________ 
Patient’s Initials: (L,  F, M) _________________ 
 Inclusion Criteria  
Yes/No (Response of “no” = patient ineligible) 
 _____ Male or female subject aged ≥ [ADDRESS_799635] is a candidate for urothelial diagnostic procedure (fresh soft-
tissue biopsy or TURBT). 
 _____ Subject meets general medical criteria for consideration of treatment with immunotherapy using a checkpoint inhibitor. 
I certify that this patient meets all inclusion and exclusion criteria  for enrollment onto 
the pre- screening portion of this study.   
______________________________  _________ _______ 
Investigator Signature     [CONTACT_603887]:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced Urothelial 
Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page [ADDRESS_799636] is used to determine patient eligibility and filed with enrolling 
physician’s signature [CONTACT_603888].  
Patient No. ______________________ 
Patient’s Initials: (L,  F, M) _________________  
5.2 Inclusion Criteri a 
Yes/No (Response of “no” = patient ineligible)  
 _____ Histologically proven transitional cell or urothelial carcinoma . 
 
 _____ P atients w ith locally advanced or metastatic urothelial carcinoma m ust meet 
one of the following:  
• Patients who are not eligible for cisplatin -containing chemotherapy AND 
whose tumors express PD -L1 (Combined Positive Score (CPS) ≥ [ADDRESS_799637]   
OR 
• Patients who are not eligible for any platinum -containing chemotherapy 
regardless of PD -L1 status . 
 _____ Metastatic (any N+ or M1) or locally advanced , unresectable (T4bN0) disease . 
 _____ Measurable disease is requ ired as determined by [CONTACT_393]  v1.1.  
 _____ Performance Status ECOG 0- 2 
 _____ Cisplatin -ineligibility based on ≥1 of the following:  
• Estimated creatinine clearance between ≥30 and <60 ml/min ( Cockcroft -
Gault formula)  
• ECOG PS >1  
• Hearing loss  
• Baseline neuropathy > grade 1 . 
• Patient refusal  
 _____ Be ≥  18 years of age on day of signing informed consent . 
 
Short Title:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced Urothelial 
Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page 26 of 82 
 _____ Serum albumin ≥ 2.8 g/dl  
 _____ Alkaline phosphatase (ALP) ≤ 3 × upper limit of normal (ULN). ALP ≤ 5 × 
ULN with documented bone metastases.  
 _____ Negative serum or urine pregnanc y test at screening for women of childbearing 
potential (see section 7.3).  
 _____ Highly  effective contraception for both male and female subjects throughout 
the study and for at l east [ADDRESS_799638] pembrolizumab  treatment administration 
if the risk of conception exists (section 7.3).  
 _____ Must have recovered from adverse effects of any prior surgery, radiotherapy or 
other antineoplastic therapy  to grade ≤2. If not recovered to grade  ≤ 2, these must be 
deemed  to be irreversible adverse events related to prior surgery and /or radiation 
therapy (such as incontinence or sexual dysfunction) per investigator clinical 
judgment.  
 _____ Recovery to baseline or ≤ Grade 2 CTCA E v.5.0 from toxicities related to any 
prior treatments, unless AE(s) are clinically nonsignificant and/or stable on supportive therapy. Alopecia, sensory neuropathy Grade ≤ 2, or other Grade  ≤ 2 not 
constituting a safety risk based on investigator’s judgment are acceptable.  
 _____ Last dose  of any radiation therapy >  [ADDRESS_799639] dose of study 
treatment . 
 _____ Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines.  
 _____ Adequate organ function as defined as:  
 Hematologic:  Absolute neutrophil count (ANC) ≥ 1.5 × 109/L (without 
granulocyte colony -stimulation factor support within 2 weeks of 
screening), platelet count ≥ 100 × 109/L (without platelet transfusion 
within 2 weeks of screening), hemoglobin ≥ 9 g/dL (ma y have been 
transfused), and white blood cell count (WBC) ≥ 2.5 × 109/L. 
 Hepatic:  Total bilirubin level ≤ 1.5 × the upper limit of normal (ULN) (≤ 
3 × ULN for subjects with Gilbert’s disease  / or unconjugated 
hyperbilirubenemia ) and AST and ALT levels ≤ 2. 5 × ULN or AST and 
ALT levels ≤ 3 ×  ULN for subjects with documented metastatic disease. 
Patient with a history of unconjugated hyperbilirubinemia with otherwise acceptable liver enzyme levels (as per above criteria) may have higher bilirubin levels.  
 Renal:  Urine protein/creatinine ratio (UPCR) ≤ 2 mg/mg (≤ 113.2 
mg/mmol) and s erum creatinine ≤  2.0 ×  ULN  or calculated creatinine 
clearance ≥  30 mL/min (≥  0.5 mL/sec) using the Cockcroft -Gault 
Short Title:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced Urothelial 
Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page 27 of 82 equation: 
• Males : (140 – age) × weight [kg]/(serum creatinine [mg/dL] × 72)  
• Females : [(140 – age) × weight (kg)/(serum creatinine [mg/dL] × 72)] 
× 0.85 
5.3 Exclusion Criteri a 
Yes/No (Response of “yes” = patient ineligible) 
 _____ P rior chemotherapy for metastatic urothelial carcinoma. 
 Prior chemotherapy for localized urot helial carcinoma that has been completed less 
than 6 months before registration. 
 _____ Variant histologies other than urothelial carcinoma will not be allowed. 
Patients with a component of variant histologies will be allowed to enroll, if urothelial carcinoma is the predominant histology per investigator judgement. Patients with any component of small cell will be excluded.  
 _____ Has received p rior treatment with cabozantinib.  
 _____ Receipt of any type of small molecule kinase inhibitor (including investigational kinase inhibitor) within [ADDRESS_799640] dose of study treatment.  
 _____ Receipt of any type of cytotoxic, biologic, or other systemic anticancer therapy (including investigational) within [ADDRESS_799641] dose of study treatment. 
 _____ Has received prior therapy with an anti -PD-1, anti- PD-L1, or anti- PD-L2 agent 
or other checkpoint inhibitors previously. 
 _____ Radiation therapy for bone metastasis ≤ [ADDRESS_799642] dose of study treatment. Subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible.  
 _____ Has known active central nervous system (CNS) meta stases and/or 
carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by [CONTACT_89181] [ADDRESS_799643] returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment. This exception does not include carcinomatous meningitis which is excluded regardless of clinical stability.  
 ____ Concomitant anticoagulation with oral coagulants except for those specified below.   
Short Title:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced Urothelial 
Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page 28 of 82 Allowed anticoagulants are the following:  
• Prophylactic use of l ow-dose aspi[INVESTIGATOR_330254] (per local applicable 
guidelines ) 
• Low-dose low molecular weight heparins (LMWH)  
• Therapeutic doses of LMWH  or anticoagulation with direct factor Xa inhibitors 
rivaroxaban, edoxaban, or api[INVESTIGATOR_603837] a stable dose of the anticoagulant for at least [ADDRESS_799644] has prothrombin time (PT) /INR or partial thromboplastin time 
(PTT) test ≥ 1.3 × ULN within [ADDRESS_799645] has uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions:  
• Cardiovascular disorders:  
o Ongoing c ongestive heart failure exacerbation or New Yo rk Heart 
Association Class 4, unstable angina pectori s, serious cardiac 
arrhythmias.  
o Uncontrolled hypertension defined as sustained blood pressure (BP) > 150 mm Hg systolic or  > 100 mm Hg diastolic despi[INVESTIGATOR_603838].  Uncontr olled hypertension needs to be 
determined based on persistently high blood pressure  readings  over 
more than 24 hours and should NOT be based on the  blood pressure 
readings from one clinic visit. Blood pressure readings done at home or 
by [CONTACT_603868]. If a blood pressure reading on 
the day of screening is high, but there are documented acceptable (≤150 
mm Hg systolic and ≤100 mm Hg diastolic)  blood pressure re adings 
prior to or after the screening visit (with or without the use of anti -
hypertensive medications), patient  will not be considered to have 
uncontrolled hypertension. 
o Stroke (including transient ischemic attack [TIA]), myocardial infarction (MI), or ot her ischemic event, or symptomatic 
thromboembolic event (e .g., deep venous thrombosis, pulmonary 
embolism)  occuring  less than or equal to [ADDRESS_799646] dose  of 
cabozantinib. [ Note: Subjects with a diagnosis of  deep vein 
thrombosis (DVT) or incidentally detected asymptomatic and sub-segmental pulmonary embolism ( PE) on routine scans are allowed if on 
a stable  dose  of anti -coagulation for at least [ADDRESS_799647] dose of 
study treatment ]  
o Clinically significan t hematuria, hematemesis, or hemoptysis of > 0.5 
teaspoon (2.5 ml) of red blood, or other history of significant bleeding (e.g., pulmonary hemorrhage) within [ADDRESS_799648] dose.  
 
Short Title:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced Urothelial 
Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page 29 of 82 • Gastrointestinal (GI) disorders including those associated with a hig h risk 
of perforation or fistula formation:  
o The subject has evidence of tumor invading the GI tract, active peptic 
ulcer disease, inflammatory bowel disease (e. g., Crohn’s disease), 
diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis, acute pancreatitis, acute obstruction of the pancreatic duct or common 
bile duct, or gastric outlet obstruction. 
o Abdominal fistula, GI perforation, bowel obstruction, or intra -
abdominal abscess within [ADDRESS_799649] dose.  
Note: Complete healing of a n intra -abdominal abscess must be confirmed 
before first dose.  
• Cavitating pulmonary lesion(s) or known endotracheal or endobronchial 
disease manifestation.  
• Lesions invading or encasing any major blood vessels. 
• Other clinically significant disorders that wo uld preclude safe study 
participation  per investigator clinical judgement.  
o Serious non- healing wound/ulcer/bone fracture.  
o Uncompensated/symptomatic hypothyroidism.  
o Moderate to severe hepatic impairment (Child -Pugh B or C).  
 _____ Other severe acute or chro nic medical conditions including immune colitis, 
inflammatory bowel disease, immune pneumonitis, pulmonary fibrosis or psychiatric 
conditions including recent (within the past year) or active suicidal ideation or behavior; or laboratory abnormalities that may increase the risk associated with study participation or study treatment administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study.  
 _____ Major surgery (e .g., GI surgery, removal or biopsy of brain metastasis) within 
[ADDRESS_799650] dose and from minor surgery (e .g., 
simple e xcision, tooth extraction) at least [ADDRESS_799651] dose. Subjects with 
clinically relevant ongoing complications per investigator clinical judgement from prior surgery are not eligible. 
 ____ Corrected QT interval calculated by [CONTACT_182097] (QTcF) > 500 ms per electrocardiogram (ECG) within [ADDRESS_799652] dose of study treatment.  
Note: If a single ECG shows a QTcF with an absolute value > [ADDRESS_799653] be performed after 
the ini tial ECG, and the average of these three consecutive results for QTcF will 
be used to determine eligibility.  
Short Title:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced Urothelial 
Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page [ADDRESS_799654] a negligible risk of metastasis or death (such as adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, ductal  carcinoma in situ treated 
surgically with curative intent, loca lized prostate cancer treated with curative intent 
and/or no intent for further treatment , or incidental prostate cancer ). 
 _____ Current use of immunosuppressive medication, EXCEPT for the following: a. intranasal, inhaled, topi[INVESTIGATOR_8826], or local steroid injection (e.g., intra -articular 
injection); b. Systemic corticosteroids at physiologic doses ≤ 10 mg/day of prednisone or equivalent; c. Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication). 
 _____ Has active autoimmune  disease currently requiring systemic treatment with 
high dose corticosteroids (dose more than physiologic replacement doses equivalent to prednisone 10 mg daily ) or disease modifying immunosuppressive agents ). 
Replacement therapy (e.g. , thyroxine, insulin, or physiologic corticosteroid 
replacement therapy for adrenal or pi[INVESTIGATOR_13002], intranasal, inhaled, topi[INVESTIGATOR_8826], or local steroid injection) is not considered a n exclusion.  
 _____ Active autoimmune disease that might deteriorate significa ntly when receiving 
an immuno- stimulatory agent per treating physician’s clinical judgment. Subjects 
with diabetes type I, vitiligo, psoriasis, or hypo-  or hyperthyroid diseases not 
requiring immunosuppressive treatment are eligible.  
 _____ Prior organ transplantation including allogenic stem- cell transplantation.  
 _____ Has known history of (non- infectious) pneumonitis that required steroids or 
has current pneumonitis. 
 _____ Has an active infection currently requiring systemic (intravenous) antibiotic 
therapy.   
 _____ Has a known history of active TB (Bacillus Tuberculosis).  
 _____ Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected).  
 _____ Has a known history of Human Immunodeficiency Virus (HIV) (H IV 1/2 
antibodies). 
 _____ Active and inactive vaccinations within [ADDRESS_799655] s or any 
component in its formulations, including known severe h ypersensitivity reactions to 
monoclonal antibodies (NCI CTCAE v.5.0 Grade ≥ 3). 
Short Title:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced Urothelial 
Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page [ADDRESS_799656] two weeks or as clinically indicated should occur prior t o the start of treatment . 
 _____ Inability to swallow tablets or evidence of impaired intestinal absorption 
I certify that this patient meets all inclusion and exclusion criteria for enrollment onto this study.  
______________________________  _________ _______ 
Investigator Signature     [CONTACT_603889]:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced Urothelial 
Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page [ADDRESS_799657] been completed as detailed on the Study Calendar (Section 8). T rial treatment may be 
administered up to 3 days before or after the scheduled Day 1 of each cycle.  
All trial treatments will be administered on an outpatient basis.  
6.1 Administration Schedule  
Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks . Sites 
should make every effort to target infusion timing to be as close to 30 minutes as possible. However, given the variability of infusion pumps from site to site, a window of - 5 minutes 
and +10 minutes is permitted (i.e., infusion time is 30 minutes: - 5 min/+10 min). 
Cabozantinib is administered at 40 mg oral daily  (with dose reductions to 20 mg daily ; a 
subsequent dose reduction to 20 mg every other day to improve tolerability is allowed) . 
Therapy continues until progression or intolerable toxicities. Study treatment ma y continue 
beyond initial  radiographic or clinical  disease progression as long as the patient is deriving 
clinical benefit from the treatment, as assessed by [CONTACT_093]. A safety analysis will be 
performed after the first 6 patients enroll and receive treatment. During this stage, the decision to continue enrollment will be made by [CONTACT_603869] (DSMC), w hen all [ADDRESS_799658] dose of 
pembrolizumab and cabozantinib. A ll available safety data will be considered in a decision to 
continue enrollment. Patients removed from therapy without evidence of progression will undergo radiological examination every 12 weeks or earlier if clinically warranted.) .  
6.2 Cabozantinib   
At stu dy sites, all study medication will be stored as described in the pharmacy manual and 
inventoried in accordance with applicable state and federal regulations.  
Clinical Supplies will be provided by [CONTACT_151982] . 
 Investigational Treatment  
Chemical Name: [CONTACT_603890] l Name: N -{4-[(6, 7-dimethoxyquinolin- 4-yl) oxy] phenyl }-N’-(4-
fluorophenyl ) cyclopropane -1, 1-dicarboxamide, (2S) -hydroxybutanedioate  
 Cabozantinib  Tablets  
Exelixis internal number: XL184  
Cabozantinib tablets are supplied as film- coated tablets containing  cabozantinib malate 
equivalent to 20 mg of cabozantinib and contain microcrystalline cellulose, lactose anhydrous, 
hydoxypropyl cellulose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate and Opadry® yellow. All tablet strengths are pr epared from a common blend and are 
distinguished by [CONTACT_7823]. The 20 mg tablets are round in shape. The components of the tablets are listed in Table 6 1.  
Short Title:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced Urothelial 
Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page 33 of 82 Table 6.1:  Cabozantinib  Tablet Components and Composition  
Ingredient  Function  % w/w  
Cabozantinib malate (25% drug load as cabozantinib)  Active Ingredient  31.7 
Microcrystalline Cellulose (Avicel PH -102) Filler  38.9 
Lactose Anhydrous (60M)  Filler  19.4 
Hydroxypropyl Cellulose (EXF)  Binder  3.0 
Croscarmellose Sodium (Ac -Di-Sol) Disenegrant  6.0 
Colloidal Silicon Dioxide,  Glidant  0.3 
Magnesium Stearate  Lubricant  0.75 
Opadry Yellow Film Coating which includes:  
- HPMC 2910/Hypromellose 6 cp  
- Titanium dioxide  
- Triacetin  
- Iron Oxide Yellow  Film Coating  4.00 
 Dose, Schedule , and Route  
Subjects will receive cabozantinib  orally at a (starting) dose of 40 mg once daily  (with dose 
reductions to 20 mg daily , and subsequently 20 mg every other day to improve tolerability is 
allowed) . The first dose will be given in clinic on day [ADDRESS_799659] of the medications at home.  Patients will be provided with a 
dosing diary  to keep track of medication taken (Appendix I).  
Cabozantinib must be taken on an empty stomach. Subjects must be instructed not to eat for at 
least [ADDRESS_799660] 8 ounces of 
water . The tablets should not be crushed. Grapefruit, grapefruit juice, s eville oranges , and their 
products should be avoided by [CONTACT_603870] . In all subjects, dose reductions 
and delays to manage toxicity are allowed under the guidelines in Section 7  below. 
 Accountability and Compliance  
Accountability and compliance should be handled per institutional policies for commercially available medications. Patients will be provided with a dosing dairy to tra ck oral dosing of 
cabozantinib (Appendix I) .  
All study drugs will be stored at the Huntsman Cancer Institute Investigational Pharmacy in accordance with Good Clinical Practice (GCP) and GMP requirements and the instructions given by [CONTACT_303139], and will be inaccessible to unauthorized personnel. The investigator, or a responsible party designated by [CONTACT_093], must maintain a careful record of the inventor y and disposition of the agent.  
An adequate record of rece ipt, distribution, and return of all study drugs must be kept in the 
form of a Drug Accountability Form. Subject compliance with the treatment and protocol 
Short Title:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced Urothelial 
Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page [ADDRESS_799661], and treatment compliance will be documented. Additional follow-up will occur for subjects with AEs related to study treatment that are ongoing at the time of this visit, and for subjects with SAEs related to study treatment that occur after the time of this visit.  
6.3 Pembrolizumab (MK -3475) Treatment  
 How Supplied, Stored, Packaged, and Labeled 
The investigator shall take responsibility for and shall take all steps to maintain appropriate records and ensure appropriate supply, storage, handling, distribution and usage of investigational product in accordance with the protocol and any applicable laws and regulations. 
Clinical Supplies will be provided as Standard of Care by [CONTACT_603871] . 
Product Descriptions 
Product Name & Potency  Dosage Form  
Pembrolizumab 50 mg Lyophilized Powder for Injection 
Pembrolizumab 100 mg/ 4mL  Solution for Injection  
 Packaging and Labeling Information 
Clinical supplies will be affixed with a clinical label in accordance with regulatory requirements.  
 Clinical Supplies Disclosure  
This trial is open -label; therefore, the subject,  the trial site personnel, the s ponsor and/or 
designee are not blinded to treatment. Drug identity (name, strength) is included in the la bel 
text; random code/disclosure envelopes or lists are not provided. 
Short Title:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced Urothelial 
Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page [ADDRESS_799662] be recorded by [CONTACT_78044].  
Clinical supplies may not be used for any purpose other than that stated in the protocol.  
 Returns and Reconciliation  
The investigator is responsible for keepi[INVESTIGATOR_35607], the 
amount dispensed to and returned by [CONTACT_748] , and the amount remaining at the 
conclusion of the trial.  
Upon completion  or termination  of the study,  all unused and/or  partially used 
investigational product will be destroyed at the site per institutional policy. It is the Investigat or’s respons ibility  to arrange for disposal of all empty containers, provided that 
procedures for proper disposal have been established according to applicable federal, state, local , and institutional  guidelines and procedures, and provided that appropriate records of 
disposal are kept.  
 Preparation and Administration  
Pembrolizumab (MK -3475) Solution for Infusion, 100 mg/ 4 mL vial : pembrolizumab 
(MK -3475) Solution for Infusion vials should be stored at  refrigerated conditions (2 – 8 °C) 
and protected from light.  
Note : vials should be stored in the original box to ensure the drug product is protected from 
light.  
Pembrolizumab (MK -3475)  infusion solutions should be prepared in 0.9% Sodium 
Chloride Injecti on, USP  (normal saline) or regional equivalent or 5% Dextrose Injection, 
USP (5% dextrose) or regional equivalent and the final concentration of pembrolizumab (MK -3475)  in the infusion solutions should be between 1 mg/mL and 10 mg/mL.  
Please note, the preferred diluent is 0.9% Sodium Chloride and 5% dextrose is only permissible if normal saline is not available.  
Local guidelines should be followed for collection of diluent information such as manufacturer, lot and expi[INVESTIGATOR_4061].  
Pembrolizumab  (MK -3475)  SHOULD NO T BE MIXED WITH OTHER DILUENTS.  
Pembrolizumab (MK -3475) solutions may be stored at room temperature for a cumulative 
time of up to 4 hours. This includes room temperature storage of admixture solutions in the IV bags and the duration of infusion 
In additi on, IV bags may be stored under refrigeration at 2 °C to 8 °C (36 °F to 46 °F) for up 
to 20 hours. If refrigerated, allow the IV bags to come to room temperature prior to use .  
Short Title:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced Urothelial 
Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page [ADDRESS_799663] between the pharmacy and the clinic 
DO NOT USE PEMBROLIZ UMAB (MK -3475) IF DISCOLORATION IS 
OBSERVED . 
DO NOT SHAKE OR FREEZE THE VIAL(S).  
DO NOT ADMINISTER THE PRODUCT AS AN (INTRAVENOUS (IV) PUSH OR 
BOLUS).  
DO NOT COMBINE, DILUTE OR ADMINISTER IT AS AN INFUSION WITH 
OTHER MEDICINAL PRODUCTS.  
Any departure from the guidance listed in this protocol, must be discussed with sponsor  
6.4 Dose Calculation 
200 mg Fixed Dose 
• 2 vials (100 mg/4 mL) 
• [ADDRESS_799664] be strictly observed throughout the preparation procedure preferably in a biologic safety cabinet or hood since no anti- microbial preservative is present in the 
solutions.  
Equilibrate required number of pembrolizumab  MK-3475 vials to room temperature. 
The preferred method of dose preparation is the volumetric method; gravimetric method is 
not permitted.  
Choose a suitable infusion bag size so that the following conditions are met: 
• Concentration of pembrolizumab MK -3475 is between 1 mg/mL and 10 mg/mL 
• The infusion volume to bag capacity ratio should not be less than 0.3. In other words, 
the bag must be filled to at least 30% of its capacity .  
Choose a suitable infusion bag material. The bag may be empty or it may contain normal saline. The following infusion bag materials are compatible with pembrolizumab (MK -
3475):  
• PVC plasticized with DEHP  
• Non-PVC (polyolefin) 
• EVA  
• PE lined polyolefin 
Short Title:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced Urothelial 
Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page 37 of 82 Calculate the volume of pembrolizumab (MK -3475) and normal saline required to prepare 
the infusion (admixture) bag . 
Volume of pembrolizumab (MK -3475)  (mL) = required dose amount (mg) / 25 (mg/mL) . 
Volume of normal saline = total infusion volume – volume of pembrolizumab (MK -3475) 
from above . 
If a bag pre -filled with normal saline is being used, remove the excess volume of normal 
saline using a sterile syringe (Polypropylene, latex -free) attached to a suitable needle. Keep 
in consideration the excess bag fill volume as well as the volume of pembrolizumab (MK -
3475)  to be added to the ba g to prepare the infusion solution. This helps ensure that the 
concentration in the bag can be accurately calculated and falls within the acceptable range of 
1 mg/mL to 10 mg/mL. If the site would like to proceed without removing excess saline they must en sure that the concentration of MK -[ADDRESS_799665] into the empty bag. Keep in consideration the volume of pembrolizumab (MK -3475)  to be added to the bag to prepare the infusion solution.  
Withdraw the required volume of pembrolizumab (MK -3475)  from the vial(s) (up to 4 mL 
from each vial) using a sterile syringe attached to a suitable needle. The vial(s) may need  to 
be inverted to remove solution. 
Volume of pembrolizumab (MK -3475)  (mL) = required dose amount (mg) / 25 (mg/mL) . 
Note:  If it is necessary to use several vials, it is advisable to withdraw from several vials into 
a suitable size single use syringe using  a new needle for each vial.  
Add the required pembrolizumab (MK -3475)  into the infusion IV bag containing normal 
saline and gently invert the bag 10- 15 times to mix the solution.  
Pembrolizumab (MK -3475)  solutions may be stored at room temperature for a cumulative 
time of up to 4 hours. This includes room temperature storage of admixture solutions in the 
IV bags and the duration of infusion.  
In addition, IV bags may be stored under refrigeration at 2 °C to 8 °C (36 °F to 46 °F) for up 
to 20 hours. If refri gerated, allow the IV bags to come to room temperature prior to use .  
DO NOT FREEZE THE PEMBROLIZUMAB (MK -3475) INFUSION SOLUTION.  
Discard any unused portion left in the vial as the product contains no preservative . 
6.6 Administration  
Pembrolizumab (MK -3475)  infusions should be administered in 30 minutes, with a window 
of -5 and +10 minutes, using an infusion pump. A central catheter is not required for 
infusion; however , if a subject has a central venous catheter in place, it is recommended that 
it be used for  the infusion.  
The following infusion set materials are compatible with (pembrolizumab) MK -3475:  
o PVC Infusion set that is plasticized using DEHP  
o PVC and tri -(2-ethylhexyl) trimellitate (TOTM) infusion set 
Short Title:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced Urothelial 
Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page 38 of 82 o Polyethylene lined PVC infusion set  
o PVC Infusion s et that is plasticized using Di- 2-ethylhexyl Terephthalate (DEHT)  
o Polyurethane set  
A sterile, non- pyrogenic, low -protein binding 0.2 to 5 µm in- line filter made of 
polyethersulfone (PES) must be used during administration to remove any adventitious 
particl es. If the infusion set does not contain 0.2 to 5 µm in- line filter, it is recommended to 
use 0.2 to 5 µm add- on filter which may contain an extension line (Note: the materials of the 
extension line and filter should be as mentioned above).  
Attach the infu sion line to the pump and prime the line, either with normal saline (at least 25 
mL) or with infusion solution as per local SOP, before starting the infusion. 
Infuse pembrolizumab (MK -3475) over approximately 30 minutes, with a window of - 5 and 
+10 minutes , through a peripheral line or indwelling catheter.  
Ensure the entire contents of the bag are dosed and all remaining drug solution in the line is 
administered according to institutional guidelines for saline flushing.  
Document volume administered accordin g to data entry guidelines.  
In case of infusion reactions, infusion rate may differ; refer to protocol section 7.[ADDRESS_799666] infusion rate should be used that will allow completion of the 
infusion within the 30 minutes. 
Maximum rate of infusion should not exceed 6.7 mL/min. through a peripheral line or 
indwelling catheter. However, when it is necessary to infuse a larger volume (i.e. , 250 mL), 
the flow rate may go as high as 10 mL/min (maximum) in order to kee p the infusion within 
the window as defined above.  
DO NOT CO -ADMINISTER OTHER DRUGS THROUGH THE SAME INFUSION 
LINE.  
UNUSED INFUSION SOLUTION FOR INJECTION SHOULD NOT BE USED FOR 
ANOTHER INFUSION OF THE SAME SUBJECT OR DIFFERENT SUBJECT.  
6.7 Accountability and  Compliance  
The investigator is responsible for keepi[INVESTIGATOR_35607], the amount dispensed to and returned by [CONTACT_748] , and the amount remaining at the 
conclusion of the trial.  
Upon completion or termination of the study, all unused and/or partially used investigational product will be destroyed at the site per institutional policy. It is the investigator’s responsibility to arrange for disposal of all empty containers, provided that procedures for proper disposal have been established according to applicable federal, state, local , and 
institutional guidelines and procedures, and provided that appropriate records of disposal are kept. 
Short Title:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced Urothelial 
Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page [ADDRESS_799667]’s welfare may be 
administered at the discretion of the investigator in keepi[INVESTIGATOR_12983]. All concomitant medication will be recorded on the case report form (CRF) including all prescription, over -the-counter (OTC), herbal supplements, and IV medications 
and fluids . If changes occur during the trial period, documentation of drug dosage, frequency, 
route, and date may also be included on the CRF.  
All concomitant medications received within [ADDRESS_799668] (including prescription and over -the-counter 
medications, transfusions, vitamins, herbal remedies, and nutritional supplements) during the period from [ADDRESS_799669] dose of study treatment are to be r ecorded in the CRF . 
 Allowed Therapi[INVESTIGATOR_014]   
• Granulocyte colony stimulating factors (G -CSF or GM -CSF) are allowed if used per 
clinical guidelines (e .g., American Society of Clinical Oncology [ASCO] or [European 
Society for Medical Oncology] ESMO guidelines) . Not allowed within two weeks prior 
to screening.  
• Drugs used to control bone loss (e.g., bisphosphonates and denosumab) are allowed if started before screening activities but may n ot be initiated or exchanged during the course 
of the study and require Princip al Investigator approval. 
• Transfusions and hormone replacement should be utilized as indicated by [CONTACT_28773]. Treatments are prohibited within two weeks prior to  screening . 
• Individualized anticoagulation therapy with heparin or direct factor Xa inhibitors rivaroxaban, edoxaban, or api[INVESTIGATOR_603839]:  
At the time of first dose of study  treatment: 
o Low dose  low molecular weight heparins  (LMWH)  for prophylactic use are allowed 
if clinically indicated and the benefit outweighs the risk per the investigator’s 
discretion.  
 Therapeutic doses of LMWH  or the direct factor Xa inhibitors rivaroxaban, 
edoxaban, or api[INVESTIGATOR_603840] , has been on a stable dose of 
anticoagulant for at least [ADDRESS_799670] dose of study treatment:  
Short Title:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced Urothelial 
Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page 40 of 82  Low dose low molecular weight heparins ( LMWH ) for prophylactic use after first 
dose of study treatment are allowed if clinically indicated (e .g., for the treatment 
of deep venous thrombosis), and the benefit outweighs the risk per the 
investigator’s discretion. For management of thromboe mbolic complications 
while on study, refer to Section 7.  
 Thereapeutic doses of LMWH or the direct factor Xa oral inhibitors rivaroxaban, edoxaban, or api[INVESTIGATOR_603841] (e.g., for the treatment of DVT), and the benefit outweights the risk per the investigator’s discretion.  
Accepted clinical guidelines regarding appropriate management while receivin g anticoagulation 
therapy with heparins must be followed. This includes, but is not limited to, subject education 
regarding potential adverse drug reactions, monitoring laboratory param eters, dose adjustments 
(e.g., due to kidney dysfunction). Caution is w arranted in settings associated with an increased 
risk for bleeding such as gastrointestinal cancers, urothelial cancers, gastrointestinal mucosal 
abnormality (e.g., mucositis), renal or hepatic impairment, thrombocytopenia, arterial hypertension, or prior  history of gastrointestinal bleed. For direct factor Xa inhibitors, the 
potential for drug -drug interaction with other concomitant medications, as well as 
gastrointestinal absorption, should be considered. Aspi[INVESTIGATOR_24241] -
inflammatory drugs (NSAIDs) should not be used concomitantly with heparin or factor Xa inhibitors due to the increased risk for bleeding complications. The risks and benefits of the use 
of anticoagulants should be reassessed on a regular basis. For more information regarding the use of anticoagulants, refer to the prescribing information of the anticoagulant and accepted clinical 
practice guidelines.  
• Potential drug interactions with cabozantinib are summarized in Section 6.8.5. 
 Prohibited or Restricted Therapy  
The following therapi[INVESTIGATOR_603842]:  
• Any investigational agent or investigational medical device.  
• Oral anticoagulation with coumarin agents (e .g., warfarin ), direct thrombin inhibitors 
(e.g., dabigatran), direct factor Xa inhibitor betrixaban,  platelet inhibitors (e .g., 
clopi[INVESTIGATOR_7745]), and chronic use of aspi[INVESTIGATOR_330282] -dose levels for cardio protection per 
local applicable guidelines), until 4 weeks after cabozantinib has been permanently discontinued.  
Short Title:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced Urothelial 
Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page 41 of 82 • Any nonprotocol systemic anticancer treatment (e.g., chemotherapy, immunotherapy, 
radionuclides, drugs or herbal products used specifically for the treatment of the cancer 
under investigation). 
The following therapi[INVESTIGATOR_603843]: 
• Local anticancer treatment including palliative radiation, ablation, embolization, or 
surgery with impact on tumor lesions should not be performed on the RECIST  v1.1 
measurable lesions.  Initiation of local anticancer therapy (e.g. , palliative radiation) will  
be considered as progression of disease. 
• Erythropoietic stimulating agents (e .g., epoetin alfa and darbepoetin alfa) should not be 
used based on a report of increased risk of tumor recurrence/progression associated with erythropoietin. 
• Concomitant medications that are known to prolong the QTc interval should be avoided in subjects who receive cabozantinib until they have permanently discontinued study treatment (refer to http://www.q tdrugs.org for a list of drugs which have the potential to 
prolong the QTc interval). 
• Chronic co-administration of cabozantinib with strong inducers of the CYP3A4 family (e.g., phenytoin, carbamazepi[INVESTIGATOR_050], rifampin, rifabutin, rifapentine, phenobarbital, and St. 
John’s Wort) may significantly decrease cabozantinib concentrations and should be avoided. Selection of alternate concomitant medications with no or minimal CYP3A4 enzyme induction potential is recommended.  
• Caution must be used when discontinuing treatment with a strong CYP3A4 inducer in a 
subject who has been concurrently receiving a stable dose of cabozantinib, as this could 
significantly increase the exposure to cabozantinib.  
• Co-administration of cabozantinib with strong inhibitors of the CYP3A4 fa mily (e .g., 
boceprevir, conivaptan, posaconazole, ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, ritonavir, lopi[INVESTIGATOR_054], telaprevir, telithromycin, and voriconazole) may increase cabozantinib concentrations and should be avoided. Grapefruit, star fruit, and Seville oranges, and their products may also increase plasma concentrations of cabozantinib and should be avoided. 
• Additional information on potential drug interactions with cabozantinib is provided in Section 6.8.5. 
 Potential Drug Interactions with Cabozantinib  
Cytochrome P450: Data from a clinical drug interaction study (Study XL184 008) show that 
clinically relevant steady state concentrations of cabozantinib appear to have no marked effect on the area under the plasma concentration -vs-time curve (AUC) of co administered 
rosiglitazone, a CYP2C8 substrate. Therefore, cabozantinib is not anticipated to markedly inhibit CYP2C8 in the clinic, and by [CONTACT_151998], is not anticipated to markedly inhibit other CYP450 isozymes that have lower [I]/Ki values compared to CYP2C8 ( i.e., CYP2C9, 
CYP2C19, CYP2D6, CYP1A2, and CYP3A4). In vitro data indicate that cabozantinib is 
Short Title:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced Urothelial 
Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page 42 of 82 unlikely to induce cytochrome P450 enzymes, except for possible induction of CYP1A1 at 
high c abozantinib concentrations (30 μM).  
Cabozantinib is a CYP3A4 substrate and a weak substrate for CYP2C9 (but not a CYP2D6, CYP2C8, CYP2C19, CYP2B6, or CYP1A2 substrate), based on data from in vitro studies. Results from a clinical pharmacology study, XL184  006, showed that concurrent 
administration of cabozantinib with the strong CYP3A4 inducer, rifampin, resulted in an approximately 77% reduction in cabozantinib exposure (AUC values) after a single dose of cabozantinib in healthy volunteers. Chronic co- administration of cabozantinib with strong 
inducers of the CYP3A4 family (e.g., phenytoin, carbamazepi[INVESTIGATOR_050], rifampin, rifabutin, rifapentine, phenobarbital, and St. John’s Wort) may significantly decrease cabozantinib concentrations. The chronic use of strong CYP3A4 inducers should be avoided. Other drugs that induce CYP3A4 should be used with caution because these drugs have the potential to decrease exposure (AUC) to cabozantinib. Selection of alternate concomitant medications with no or minimal CYP3A4 enzyme induction potential is recommended.  
Results from a clinical pharmacology study, XL184 007, showed that concurrent 
administration of cabozantinib with the strong CYP3A4 inhibitor, ketoconazole, resulted in a 38% increase in the cabozantinib exposure (AUC values) after a single dose of cabozantinib in healthy volunteers. Co-administration of cabozantinib with strong inhibitors of the 
CYP3A4 family (e .g., boceprevir, conivaptan, posaconazole, ketoconazole, itraconazole, 
clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, ritonavir, lopi[INVESTIGATOR_054], 
telaprevir, telithromycin, and voriconazole) may increase cabozantinib concentrations. Grapefruit, star fruit and Seville oranges, and their products may also increase plasma concentrations of cabozantinib and are prohibited. Strong CYP3A4 inhibitors should be avoided and other drugs that inhibit CYP3A4 should be used with caution because these drugs have the potential to increase exposure (AUC) to cabozantinib. Selection of alternate concomitant medications with no or minimal CYP3A4 enzyme inhibition potential is recommended.  
Please refer to the drug interaction tables at the following websites for lists of substrates, 
inducers, and inhibitors of selected CYP450 isozyme pathways: http://medicine.iupui.edu/clinpharm/ddis/table.aspx
 OR http://www.fda.gov/Drugs/ 
DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm080499.htm).  
Protein Binding:
  Cabozantinib is hig hly bound (≥ 99.7%) to human plasma proteins. 
Therefore, highly protein bound drugs should be used with caution with cabozantinib 
because there is a potential displacement interaction that could increase free concentrations of cabozantinib and/or a co- admi nistered highly protein bound drug (and a corresponding 
increase in pharmacologic effect).  
Other Interactions :
  Food may increase exposure levels of cabozantinib by 57%, fasting 
recommendations should be followed. In vitro data suggest that cabozantinib is unlikely to be a substrate for P -glycoprotein, but it does appear to have the potential to inhibit the P-
glycoprotein transport activity. Therefore, cabozantinib may have the potential to increase plasma concentrations of co -administered substrates of P- glycoprotein. Additional details 
related to these overall c onclusions can be found in the Investigator ’s Brochure. 
Short Title:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced Urothelial 
Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page 43 of 82 Administration of the proton pump inhibitor (PPI) esomeprazole resulted in no clinically -
relevant effect on cabozantinib plasma PK in healthy volunteers. Therefore, concomitant use 
of gastric pH modifying agents ( i.e., PPIs, H2 receptor antagonists, and antacids) is not 
contraindicated in subjects administered cabozantinib. 
Additional details regarding potential drug interactions with cabozantini b can be found in the 
investigator brochure.  
Cabozantinib was shown to be a substrate of drug transporter MRP2 in an in vitro assay. 
Administration of MRP2 inhibitors to subjects may result in increases in cabozantinib plasma concentrations. 
Table 6.2: Clinically  Significant Interactions  Involving Drugs  that  Affect Cabozantinib  
Strong  CYP3A4  Inhibitors  
Clinical  Implications:  • Concomitant  use of cabozantinib  with a strong CYP3A4  
inhibitor  increased  the exposure  of cabozantinib 
compared  to the use of cabozantinib  alone  
• Increased  cabozantinib exposure  may  increase the  risk of 
exposure -related  toxicity.  
Prevention  or 
Management:  Reduce the dosage  of cabozantinib  if concomitant  use with 
strong  CYP3A4  inhibitors  cannot  be avoided   
Examples:  Boceprevir,  clarithromycin,  conivaptan,  grapefruit  juicea, 
indinavir,  itraconazole,  ketoconazole, lopi[INVESTIGATOR_054]/ritonavir,  
nefazodone, nelfinavir,  posaconazole,  ritonavir,  saquinavir,  
telithromycin,  and voriconazole  
Strong  CYP3A4  Inducers  
Clinical  Implications:  • Concomitant  use of cabozantinib  with a strong 
CYP3A4  inducer decreased  the exposure  of 
cabozantinib compared  to the use of cabozantinib alone  
• Decreased  cabozantinib  exposure  may  lead to reduced  
efficacy . 
Prevention  or 
Management:  Increase the dosage  of cabozantinib  if concomitant  use 
with strong  CYP3A4  inducers  cannot  be avoided  
Examples:  Rifampin,  phenytoin,  carbamazepi[INVESTIGATOR_050],  phenobarbital,  
rifabutin,  rifapentine,  and St. John’s  Wortb 
a. The effect  of grapefruit  juice varies  widely  among  brands and is concentration -, dose-, and preparation -
dependent.  Studies  have  shown  that it can be classified  as a “strong  CYP3A inhibitor”  when  a certain  
preparation  was used (e.g.,  high dose, double  strength)  or as a “moderate CYP3A inhibitor”  when  another  
preparation  was used (e.g.,  low dose,  single  strength).  
b. The effect  of St. John’s  Wort  varies  widely  and is preparation -dependent  and is prohibited.  
The Exclusion Criteria describes other medications which are prohibited in this trial.  
There are no prohibited therapi[INVESTIGATOR_3927] -Treatment Follow -up Phase.  
Short Title:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced Urothelial 
Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page 44 of 82 6.9 Duration of Therapy  
Subjects enrolled after Amendment 7 (version date 08NOV2021)  will remain on study 
treatment for up to 12 months. After consultation with PI, s ubjects enrolled prior to 
Amendment 7 (ve rsion date 08NOV2021)  who ha ve demonstrated a response to study 
treatment may  continue beyond [ADDRESS_799671] be withdrawn from the study treatment for the following reasons:  
• Subject withdraws consent from the stud y treatment and/or study procedures. A subject 
must be removed from the trial at his/her own request or at the request of his/her legally 
acceptable representative. At any time during the trial and without giving reasons, a subject may decline to participa te further. The subject will not suffer any disadvantage as 
a result.  
• Radiographic disease progression by [CONTACT_393]  v1.1 (progression must be confirmed with 
follow up scan no less than [ADDRESS_799672] scan shows disease progression) . Study treatment may  continue beyond initial radiographic disease 
progression as long as the patient is deriving clinical benefit from the treatment, as assessed by [CONTACT_093].   
• Progressive disease (PD) , without clinical benefit,  as determined by [CONTACT_093].  
• Specific conditions described in the Management of Adverse Events Section 7. 
• An AE or intercurrent illness that in the opi[INVESTIGATOR_603844]’s withdrawal from study treatment.  
• Subject is lost to follow -up. 
• Necessity for treatment with other t reatment prohibited by [CONTACT_990].  
• Sexually active subjects who refuse to use medically accepted barrier methods of contraception (e .g., male condom, female condom) during the course of the study and for 
120 days  after dis continuation of study treatment.  
• Women who becom e pregnant or are breastfeeding.  
• If the subject does not recover from his or her toxicities to tolerable Grade ≤ [ADDRESS_799673] may be able to restart therapy with a dose reduction upon resolution of the toxicity . 
• Request by [CONTACT_603872]. 
• Significant noncompliance with the protocol schedule in the opi[INVESTIGATOR_871].  
Short Title:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced Urothelial 
Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page 45 of 82 • The starting dose of Cabozantinib study treatment will be 40 mg once daily (qd) , (with 
dose reduction allowed for documented adverse events to 20 mg daily , and then to 20 mg 
every other day to improve tolerability .)  
 
Subjects may be withdrawn from the study for the following reasons:  
• The subject is non- compliant with study drug, trial procedures, or both; including the use 
of anti -cancer therapy not prescribed by [CONTACT_4690]. 
• If, in the investigator's opi[INVESTIGATOR_1649], continuation of the trial would be harmful to the subject's well-being.  
• Development of an intercurrent illness or situation which would, in the judgment of the investigator, s ignificantly affect assessments of clinical status and trial endpoints.  
• Deterioration of ECOG performance status to 4.  
7 TOXICITIES AND DOSEAGE MODIFICATION 
This study will utilize the CTCAE (NCI Common Terminology Criteria for Adverse Events) Version 5.[ADDRESS_799674] dose of cabozanti nib treatment. Subjects will be instructed to notify their physician 
immediately at the onset of any AE. Causality assessment of AEs will be determined  by [CONTACT_1275]. AE severity will be graded by [CONTACT_603873] v.5.0. The following should be taken into consideration in decisions regarding dose modifications (reductions or interruption):  
• As a general approach , all AEs should be managed with supportive care at the earliest 
signs of toxicity considered related to the study tre atment. Should this be ineffective, 
dose interruptions and/or reductions should be considered to prevent worsening of toxicity.  
• The assigned starting dose for cabozantinib is 40 mg/day . Dose reductions are permitted 
per PI [INVESTIGATOR_9106]  (see Table 7.1 ). Dose re --escalation level (See 7.2)  of cabozantinib is 
permitted.  
• Dose interruptions and/or reductions should be implemented for unacceptable toxicity. Doses may be modified at any time while on study.  
• Interruption of cabozantinib treatment for AEs may occur at  any time per investigator 
discretion. If treatment is interrupted due to AEs for more than [ADDRESS_799675] may be able t o restart therapy with a dose 
reduction upon resolution of the toxicity.  
Short Title:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced Urothelial 
Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page 46 of 82 • Dose interruptions for reason(s) other than related AEs (e.g., surgical procedures) can be 
longer than 6 weeks per the discretion of the investigator. 
Table 7.1 
Assigned dose  Dose Level Reduction  
40-mg cabozantinib oral , qd 20-mg cabozantinib oral , qd. 
20-mg cabozantinib oral, qd  20-mg cabozantinib oral, qad  
 
Table 7.2 
Assigned dose  Dose Level Escalation  
20-mg cabozantinib, oral qad  20-mg cabozantinib, oral qd  
20-mg cabozantinib , oral qd  40-mg cabozantinib , oral qd  
Table 7.3: Dose Modifications of Cabozantinib for Treatment- Related AEs  
CTCAE v. 5.0 Grade  Recommended Guidelines for Managementa 
Grade 1 AEs  Add supportive care as indicated. Continue cabozantinib treatment 
at the current dose level if AE is manageable and tolerable.  
Grade 2 AEs that are 
tolerable and are easily 
managed  
 
Grade 2 AEs that  are 
intolerable  and cannot be 
adequately managed   Continue cabozantinib treatment at the current dose level with  
supportive care. 
 
At the discretion of the investigator, cabozantinib should be dose 
reduced or interrupted. Note: It is recommended that dose holds be as brief as possible.  
Grade 3 AEs (except 
clinically non- relevant 
laboratory abnormalities)  Cabozantinib should be interrupted unless the toxicity can be easily 
managed with a dose reduction and optimal medical care.  
Note: It is recommended that dose holds be as brief as possible.  
Grade 4 AEs (except 
clinically non- relevant 
laboratory abnormali ties) Subjects should have cabozantinib interrupted immediately.  
Permanently discontinue all study  treatment  unless the following 
criteria are met:  
• Subject is deriving clear clinical benefit as determined by [CONTACT_093]  
• Toxicity can be managed with a dose reduction following 
recovery to Grade  1 (or baseline) and optimal medical care  
Note : The dose delay and modification criteria for specific medical con ditions are provided in Section 7.1 .1. 
For re -treatment criteria of study treatment after a dose hold see Section 7 .1.1. 
a Study treatment dose adjustment is only needed if the toxicity was deemed related to cabozantinib 
treatment or had an unclear relationship  to cabozantinib treatment.  
 Guidelines for Management of Potential Adverse Events  for Cabozantinib 
Management of severe or intolerable adverse reactions may require temporary dose reduction 
and/or interruption for cabozantinib.  
All study treatment should be permanently discontinued for the following AEs: visceral 
perforation or fistula formation, severe hemorrhage, serious arterial thromboembolic events, 
Short Title:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced Urothelial 
Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page 47 of 82 nephrotic syndrome, hypertensive emergency, persistent uncontrolled hypertension despi[INVESTIGATOR_115047], and reversible  posterior leukoencephalopathy syndrome  
(RPLS ). 
Gastrointestinal perforation, GI fistula, and intra- abdominal and pelvic abscess:  After 
starting treatment with cabozantinib, subjects should be monitored for early signs of GI perforation such as abdominal pain, nausea, emesis, constipation, and fever especially if known risk factors for developi[INVESTIGATOR_603845].  
Permanently discontinue  all study treatment and initiate appropriate management in subjects 
who have been diagnosed with GI  perforation or fistula.  
Diarrhea:  Subjects should be instructed to notify their physician immediately at the first 
signs of poorly formed or loose stool or an increased frequency of bowel movements. Guidelines for the evaluation and management of diarrhea  are shown in Table 7.4. 
Administration of antidiarrheal/antimotility  agents is recommended at the first sign of 
diarrhea as initial management. Some subjects may require concomitant treatment with more than one antidiarrheal agent. When therapy with antidiarrheal agents does not control the diarrhea to tolerable levels, cabozantinib should be temporarily interrupted or dose reduced. When the diarrhea is controlled, retreatment with cabozantinib may be acceptable per investigator decision. In addition, general supportive measures should be implemented such 
as continuous oral  isotonic hydration, correction of fluid and electrolyte abnormalities, small 
frequent meals, and stoppi[INVESTIGATOR_151947] -containing products, high -fat meals, and alcohol. 
Recurrent or prolonged diarrhea can be associated with anal or perianal skin erosions which 
increase the risk for anal abscesses, fistulas, or proctitis. Good personal hygiene should be emphasized. Regular examinations of the perianal region should be perf ormed whenever 
diarrhea has occurred during treatment with cabozantinib. Infections of the perianal region 
should be treated per local guidelines.  
Table 7.4:  Management of Diarrhea Associated with Cabozantinib  
Status  Management  
Tolerable Grade 1 -2 
(durat ion <  48 h) • Continue with study treatment and consider dose reduction  
• Initiate treatment with an antidiarrheal agent (e .g., loperamide 4 mg followed by 
2 mg after each epi[INVESTIGATOR_76337] [maximum: 16 mg loperamide per day])  
• Dietary modifications (e .g., small lactose -free meals, bananas , and rice)  
• Intake of isotonic fluids (1 -1.5 L/day)  
• Re-assess after 24 hours:  
o Diarrhea resolving to baseline bowel habits: gradually add solid foods and 
permanently discontinue  or decrease antidiarrheal treatment after 12 h 
diarrhea- free interval  
o Diarrhea not resolving: Continue/resume antidiarrheal treatment  
Intolerable Grade 2,  
Grade 2 > 48 h,  
or ≥ Grade 3  • Interrupt study treatment  
• Ask subject to attend clinic  
• Rule out infe ction (e .g., stool sample for culture)  
o Administer antibiotics as needed (e .g., if fever or Grade 3 -4 neutropenia 
persists >  24 h) 
• Administer fluids (1 -1.5 L/day orally or IV, as appropriate) for hydration or to 
correct electrolyte abnormalities  
Short Title:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced Urothelial 
Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page 48 of 82 • For Grade 3 -4 or complicated lower grade diarrhea consider hospi[INVESTIGATOR_603846] 
• Re-assess after 24 h  
o Diarrhea resolving to baseline bowel habits or Grade ≤  1: consider restarting 
study treatment at reduced dose 
o Diarrhea not resolving: Start and or continu e antidiarrheal treatment (e .g., 
loperamide 4 mg followed by 2 mg after each epi[INVESTIGATOR_76337] 
[maximum: 16 mg loperamide per day]). Consider starting second line 
antidiarrheal or referral to gastroenterologist  
Nausea and vomiting: Antiemetic agents are recommended as clinically appropriate for 
treatment or prophylaxis of nausea and vomiting, along with supportive care. Dehydration and electrolyte abnormalities may be associated with vomiting and monitoring for and correction of flui d and electrolyte disturbances should be implemented. Antiemetic 
medications should be assessed for potential drug interactions (refer to Section 6.8.5).  
Non- Gastrointestinal Fistula: Complications from  radiation therapy especially of the 
thoracic cavity i ncluding mediastinum have been identified as a possible predisposing risk 
factor for non -GI fistula formation in subjects undergoing treatment with VEGF pathway 
inhibitors.  
Permanently discontinue  all study  treatment and initiate appropriate management in  subjects 
who have been diagnosed with a non GI fistula.  
Hemorrhage: Hemorrhagic events, including serious and sometimes fatal events, have been 
reported with cabozantinib. Subjects should be monitored for bleeding events with serial complete blood counts and physical examination while on study. The risk of hemorrhage in cabozantinib- treated subjects with brain metastases has not been thoroughly analyzed. 
Subjects enrolled with treated and stable brain metastases should be monitored with a high index of sus pi[INVESTIGATOR_461735] a CNS hemorrhage occur. 
All study treatment should be permanently discontinue d in subjects  with serious and life -
threatening bleeding events or recent hemoptysis (≥ 2.5 mL of red blood).  
Thromboembolic events: Thromboembolic events are frequent in cancer subjects due to 
procoagulant changes induced by [CONTACT_603874]. DVT and pulmonary embolism have been observed in clinical studies with cabozantinib, including fatal events. 
Subjects who develop a  pulmonary embolism and/or DVT should have study treatment 
interrupted until therapeutic anticoagulation is established. Treatment with cabozantinib may be resumed in subjects with pulmonary embolism or DVT if it is determined that the event is uncomplicat ed and that the subject is deriving clinical benefit from cabozantinib treatment 
and that the anticoagulation does not place them at a significant risk that outweighs the benefit of resuming treatment per discretion of the investigator and according to individual protocols. Therapeutic doses of LMWH or the direct factor Xa oral inhibitors rivoroxaban, edoxaban, or api[INVESTIGATOR_603847]. Other oral anticoagulants including coumarin agents (e.g., warfarin), platelet inhi bitors (e.g., 
clopi[INVESTIGATOR_7745]), and chronic use of aspi[INVESTIGATOR_603848], until 4 weeks ater cabozantinib has been permanently discontinued. 
Short Title:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced Urothelial 
Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page 49 of 82 Arterial thrombotic events (e .g., TIA, MI ) have been observed in studies with cabozantinib. 
Subjects should be evaluated for pre -existing risk factors for arterial thrombotic events such 
as diabetes mellitus, hyperlipi[INVESTIGATOR_035], hypertension, coronary artery disease, history of 
tobacco use, and cardi ac and/or thromboembolic events that occurred prior to initiation of 
study treatment. Further treatment with cabozantinib should be discontinued in subjects who develop an acute MI, cerebral infarction, or any other clinically significant arterial thromboe mbolic complication.  
Hypertension: Table 7.[ADDRESS_799676] measurement.  
All study treatment should be permanently di scontinue d in subjects with  hypertensive 
emergency.  
Table 7.5:  Management of Hypertension Associated with Cabozantinib  
Criteria for Dose Modifications  Treatment/Cabozantinib Dose Modification  
Subjects NOT receiving optimized anti -hypertensive therapy  
> 150 mm Hg (systolic)a and <  160 mm 
Hg 
OR 
> 100 mm Hg (diastolic) and < 110 mm 
Hg 
 • Optimize antihypertensive medications by [CONTACT_603875]/or increase 
dose of existing medications.  
• Reduce cabozantinib treatment by [CONTACT_603876] (usually to include 3 agents) does 
not result in BP <150 mm Hg systolic or <100 mm Hg 
diastolic  
• If subject is symptomatic interrupt cabozantinib treatment  
≥ 160 mm Hg (systolic)  
OR 
≥ 110 mm Hg (diastolic)  • Reduce cabozantinib by [CONTACT_603877]  
• Add new or additional anti -hypertensive medications and/or 
increase dose of existing medications and monitor subject closely for hypotension. If optimized antihypertensive 
therapy (usually to include 3  agents) does not result in BP <  
150 mm Hg systolic or <  100 mm Hg diastolic, cabozantinib 
treatment should be  interrupted  
• Cabozantinib treatment should be dose interrupted if upper 
limits of systolic  BP (≥  160 mm Hg) are sustained and not 
adequately manageable or if systolic BP is > 180 mm Hg or 
diastolic BP >  [ADDRESS_799677] is symptomatic  
• Re-start cabozantinib treatment at the most tolerable dose and 
re-escalate only if BP falls to and is s ustained at < 150 mm 
Hg systolic and <  100 mm Hg diastolic  
Hypertensive emergencyc • Decide to initiate or adjust antihypertensive . Permanently 
discontinue  all study  treatment  
a The investigator may approve treatment at a lower threshold than systolic BP >150 or diastolic BP >[ADDRESS_799678].  
b Permitted dose levels are defined by [CONTACT_603878] [INVESTIGATOR_9106].  
c Hypertensive emergency is defined as uncontrolled elevated BP with clinical  evidence of progressive or impending 
end-organ damage (e. g., myocardial infarction/ischemia, intracranial hemorrhage, cerebral ischemia, pulmonary 
edema, encephalopathy, kidney damage).  
Short Title:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced Urothelial 
Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page 50 of 82 Stomatitis and Mucositis:  Preventive measures may include a comprehensive oral 
examination to identify and treat any potential risk for complications before study treatment 
is initiated. Appropriate correction of local factors should be instituted as indicated, such as modification of ill- fitting dentures and appropriate care of gingivitis. During treatment with 
cabozantinib, good oral hygiene and standard local treatments such as non- traumatic and 
non-irritating cleansing, and oral rinses (e .g., with a weak solution of salt and baking soda) 
should be maintained. Li ps should be kept moisturized with lip balm. The use of lipstick, lip-
gloss, and Vaseline should be avoided.  
Local treatment should be instituted at the earliest onset of symptoms. Obtain bacterial/viral culture if oral infection is suspected and treat inf ection as clinically indicated.  
Skin and Subcutaneous Tissue Disorders: Wound healing and surgery: Cabozantinib has the potential to cause wound healing complications and wound dehiscence , which may even 
occur long after a wound has been considered healed . Therefore, surgical and traumatic 
wounds must not only be completely healed prior to starting cabozantinib treatment but must also be monitored for wound dehiscence, wound infection, and other signs of impaired wound healing while the subject is being tr eated with cabozantinib. If dehiscence occurs, 
cabozantinib treatment should not be restarted until complete healing has taken place.  
Treatment with cabozantinib should be stopped at least 28 days prior to scheduled surgery. 
The decision to resume treatment with cabozantinib after surgery should be based on clinical 
judgment of adequate wound healing.  
Palmar -plantar erythrodysesthesia syndrome (PPES; also known as hand- foot syndrome), 
skin rash (including blister, erythematous rash, macular rash, skin exfoliation, dermatitis acneiform, and papular rash), pruritus, dry skin, erythema, pi[INVESTIGATOR_9491], and alopecia 
have been reported with cabozantinib. All subjects on study should be advised on prophylactic measures including the use of emollients, removal of calluses, avoidance of exposure of hands and feet to hot water leading to vasodilatation, protection of pressure -
sensitive areas of hands and feet, and use of cotton gloves and socks to prevent injury and keep the palms and soles dry.  
Early manifestati ons include tingling, numbness, mild hyperkeratosis, and symmetrical red 
and swollen areas on the palms and soles. The lateral sides of the fingers or periungual zones may also be affected. Adequate interventions are required to prevent worsening of skin symptoms such as blisters, desquamations, ulcerations, or necrosis of affected areas. 
Analgesics may be required for pain control. 
Aggressive management of symptoms is recommended, including early dermatology referral. 
Treatment recommendations in response to PPES are summarized in Table 7.6. 
Table 7.6:  Management of Hand -Foot Syndrome (PPES) Associated with Cabozantinib  
CTCAE v .5.0 Grade  Action To Be Taken  
Grade 1  Cabozantinib treatment may be continued at the current dose if PPES is clinically 
insignificant and tolerable. Otherwise, cabozantinib should be reduced to the next 
lower dose level.a Start urea 20% cream twice daily AND clobetasol 0.05% 
cream once daily. Reassess at least weekly; if PPES worsens at any time or does 
not improve after 2 weeks, proceed to the intervention guidelines for Grade  2. 
Short Title:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced Urothelial 
Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page 51 of 82 Grade 2  Cabozantinib treatment may be continued if PPES is tolerated. Cabozantinib 
should be dose reduced or inte rrupted if PPES is intolerable. Continue urea 20% 
cream twice daily AND high potency steroid cream (e. g., clobetasol 0.05%) once 
daily and add analgesics (e. g., NSAIDs/gamma -aminobutyric acid agonists) for 
pain control if needed. Reassess at least weekly; if PPES worsens or affects 
self-care, proceed to the intervention guidelines for Grade  3. 
Grade 3  Interrupt cabozantinib treatment until severity decreases to Grade 1 or 0. 
Continue treatment of skin reaction with high potency steroid cream (e .g., 
clobetasol 0.05%) twice daily AND analgesics. Resume study drug at a reduced 
dose if PPES recovers to Grade ≤  1. Permanently discontinue  subject  from study 
treatment if PPES does not improve within 6  weeks.  
CTCAE, Common Terminology Criteria for Adverse E vents; NSAID,  non-steroidal anti -inflammatory drug; 
PPES,  palmar plantar erythrodysesthesia syndrome.  
a Permitted dose levels are defined by [CONTACT_7905].  
Osteonecrosis:  Osteonecrosis has been reported in subjects treated with cabozantinib. 
Additional risk factors include use of bisphosphonates and denosumab, chemotherapy and 
anti-angiogenic drugs, use of corticosteroids, local radiotherapy, and dental or orofacial 
surgery  procedures.  
Osteonecrosis of the jaw (ONJ) can manifest as jaw pain, osteomyelitis, osteitis, bone erosion, tooth or periodontal infection, toothache, gingival ulceration, or gingival erosion. Persistent pain or slow healing of the mouth or jaw after dental surgery may also be manifestations of osteonecrosis. 
Advise subjects regarding oral hygiene practice and to quickly report symptoms to 
investigator. Caution should be used in subjects receiving bisphosphonates. 
Invasive dental procedures should be avoi ded. In cases where dental procedures are 
unavoidable, treatment with cabozantinib should be interrupted for at least 4 weeks prior to 
the procedure and resumed after complete wound healing has occurred. Bone healing may often require a protracted time.  
Proteinuria:  Proteinuria has been reported with cabozantinib. Proteinuria should be 
monitored by [CONTACT_461792]. Table 7.7 provides treatment guidelines for proteinuria deemed related to cabozantinib.  
All study treatment should be permanently discontinue d in subjects who develop nephrotic 
syndrome (proteinuria > 3.5 grams per day in combination with low blood protein levels, high cholesterol levels, high triglyceride levels, and edema).  
Table 7.7:  Management of Proteinuria Associated with Cabozantinib  
Sever ity of Proteinuria 
(UPCR)  Management of Proteinuria  
≤ 1 mg/mg  
(≤ 113.1 mg/mmol)  • No change in cabozantinib treatment or monitoring  
Short Title:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced Urothelial 
Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page 52 of 82 > 1 and <  3.5 mg/mg  
(> 113.1 and < 395.9 
mg/mmol)  
 
 • Consider confirming with a 24 -h protein assessment within 7 days  
• No change in cabozantinib treatment required if UPCR ≤ 2 mg/mg or 
urine protein ≤ 2 g/24 h on 24 -h urine collection.  
• Dose reduce or interrupt cabozantinib treatment if UPCR > 2 mg/mg on repeat UPCR testing or urine protein > 2 g/24 h on 24- h urine collection.  
Continue cabozantinib on a reduced dose if UPCR decreases to < 2 mg/mg. Consider interrupting cabozantinib treatment if UPCR remains > 
2 mg/mg despi[INVESTIGATOR_040] a dose reduction until UPCR decreases to < 2 mg/mg. 
Restart cabozantinib treatment at a reduced dose aft er a dose 
interruption.  
• Repeat UPCR within 7 days and once per week. If UPCR < 1 mg/mg on 
2 consecutive readings, UPCR monitoring can revert to protocol -specific 
times. (Second reading is confirmatory and can be done within [ADDRESS_799679] reading.) If UPC R remains > 1 mg/mg and < 2 mg/mg for 1 
month or is determined to be stable (< 20% change) for 1 month, check 
urine protein/creatinine per protocol or as clinically indicated.  
≥ 3.5 mg/mg  
(≥ 395.9 mg/mmol)  • Interrupt cabozantinib treatment pending repeat UPCR within 7  days 
and/or 24- h urine protein.  
• If ≥ 3.5 mg/mg on repeat UPCR, continue to interrupt cabozantinib 
treatment and check UPCR every 7 days. If UPCR decreases to < 2 mg/mg, restart cabozantinib treatment at a reduced dose and monitoring 
of urine  protein/creatinine should continue weekly until the UPCR 
decreases to < 1 mg/mg. If UPCR remains > 1 mg/mg and < 2 mg/mg 
for 1 month or is determined to be stable (< 20% change) for 1 month, 
check urine protein/creatinine per protocol or as clinically ind icated.  
Nephrotic syndrome  • Permanently discontinue  all study treatment  
RCC, renal cell carcinoma; UC, urothelial carcinoma; UPCR, urine protein/creatinine ratio.  
Nervous System Disorders:  Cabozantinib appears to represent minimal risk of adverse 
neurological effects based on nonclinical Good Laboratory Practice (GLP) -compliant 
toxicology studies. Dysphonia, dysgeusia, headache, dizziness, confusional state, convulsion, 
depression, memory i mpairment, hypoesthesia, peripheral neuropathy, insomnia, ataxia, and 
encephalopathy have been observed in clinical studies with cabozantinib. The development of any new or progressive, unexplained neurological symptoms should be assessed for underlying ca uses.  
RPLS has been reported. RPLS should be considered in any subject presenting with seizures, headache, visual disturbances, confusion or altered mental function. All study  treatment 
should be permanently discontinue d in subjects  with RPLS.  
Hepatocellul ar Toxicity : Investigators should monitor for DILI diligently and report any 
potential events.  
Elevation of aminotransferases (ALT and AST)  and bilirubin have been observed during 
treatment with cabozantinib. It is recommended that subjects with elevation s of ALT, AST, 
and/or bilirubin have more frequent laboratory monitoring of these parameters. If possible, 
Short Title:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced Urothelial 
Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page [ADDRESS_799680], or bilirubin, and other potential ca uses for these increases 
(e.g., cancer -related infection) should be evaluated. Management guidance for hepatoxocity  
related to cabozantinib is provided in Table 7.8.  
 
Table 7.8: Management of Liver Function Laboratory Abnormalities Related to Cabozantinib  
 
Severity of ALT, AST, Total Bilirubin Elevations by 
[CONTACT_3989] v.5.0    
Treatment Dose Modification  
Grade 1   
• Dose adjustment is usually not required.  
• Consider discontinuing concomitant hepatotoxic 
medications and add supportive care as indicated.  
 
Grade 2   
• Interrupt study treatment if lasting longer than [ADDRESS_799681], 
and bilirubin.  
• Restart study treatment after lab abnormalities have 
resolved to at least CTCAE Grade ≤ 1 or baseline.  
 
Grade ≥ 3   
• Interrupt study treatment and consider more frequent monitoring of ALT, AST, and bilirubin.  
• Restart study treatment at a reduced dose after lab abnormalities have resolved to at least CTCAE Grade ≤ 1 or baseline.  
• Discontinue if lab abnormalities cannot be reversed 
despi[INVESTIGATOR_603849].  • Discontinue if drug- related ALT or AST>[ADDRESS_799682] in 
combination with total bilirubin >[ADDRESS_799683] without 
other reasonable explanation, consistent with drug -
induced liver injury (DILI).  
 
ALT, alanine aminotransferase; AST, aspa rtate aminotransferase; CTCAE v.5.0 , Common Terminology Criteria for Adverse 
Events version 4  
Elevations of aminotransferases when hepatic metastases are present may not require dose 
modifications if there are no progressive changes in the aminotransferases (less than a doubling) and if there are no progressive elevations in serum bilirubin concent ration or 
coagulation factors.  
The following condition requires discontinuation of cabozantinib:  
Drug -related ALT or AST >3 × ULN  in combination with total bilirubin >2  × ULN  witho ut 
other reasonable explanation, consistent with drug -induced liver injury  (DILI).  
Infections and Infestations: Infections are commonly observed in cancer subjects. 
Predisposing risk factor include a decreased immune status (e .g., after myelosuppressive  
anticancer therapi[INVESTIGATOR_014], splenectomy), destructive growth of the underlying malignancy 
Short Title:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced Urothelial 
Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page [ADDRESS_799684].  
Blood and Lymphatic System Disorders:  Hematological toxicities ( i.e., neutropenia and 
thrombocytopenia) and associated complications have been observed after administration of cabozantinib and may be managed with dose interruptions and/or dose reductions. Subjects with hematologic toxicities may require additional or more frequent laboratory tests according to institutional guidelines.  
Dose redu ctions or dose interruptions for hematological toxicities are not mandated but can 
be applied as clinically indicated. Supportive care for thrombocytopenia or anemia, such as transfusions, may be managed according to institutional guidelines. The use of colony -
stimulating growth factors should be considered. Febrile neutropenia or evidence of infection associated with neutropenia must be assessed immediately and treated appropriately and in a timely manner according to institutional guidelines.  
Fatigue:  Com mon causes of fatigue, such as anemia, deconditioning, emotional distress 
(depression and/or anxiety), poor nutrition, dehydration, sleep disturbance, and hypothyroidism should be ruled out and treated according to standard of care. 
Pharmacological managem ent should be considered after disease specific morbidities have 
been excluded when not prohibited.  
Weight Loss:  Anorexia and weight loss should be managed according to local standard of 
care including nutritional support. Pharmacologic therapy should be considered for appetite 
enhancement when not prohibited by a particular protocol. Corrected QT Prolongation:  The effect of orally administered cabozantinib [ADDRESS_799685] form morphology or new rhythms were not observed. No cabozantini b-treated 
subjects in this study had a QTcF > 500 ms. Review of the larger safety database (~[ADDRESS_799686] -marketing experience) 
confirmed the absence of safety concerns associated with QT prolongation . There were no 
events of torsades de pointes reported.  
Concomitant treatment with strong cytochrome P450 (CYP) 3A4 inhibitors, which may increase cabozantinib plasma concentrations, should be avoided.  
If at any time on study there is an increase in QTcF to an absolute value > [ADDRESS_799687] be performed with intervals not less than 3 min apart within 30 min after the initial ECG.  
If the average QTcF from the three ECGs is > [ADDRESS_799688] be taken:  
• Interrupt cabozanti nib treatment. 
Short Title:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced Urothelial 
Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page 55 of 82 • Hospi[INVESTIGATOR_603850] (e .g., with palpi[INVESTIGATOR_814], dizziness, syncope, 
orthostatic hypotension, a significant ventricular arrhythmia on ECG) for a thorough 
cardiology evaluation and management . 
• Consider cardiology consultation for as ymptomatic subjects for evaluation and 
management . 
• Check electrolytes, especially magnesium, potassium , and calcium; correct 
abnormalities as clinically indicated . 
• Check concomitant medications for any medication that may have contributed to QT prolongation, and if possible, permanently discontinue  these medications 
(http://www.qtdrugs.org) . 
• Repeat ECG triplicates hourly until the average QTcF is ≤ [ADDRESS_799689] resolved. Cabozantinib treatment may be restarted at a reduced dose l evel if all of the following conditions are met: 
• Symptoms are determined to be unrelated to the QT interval prolongation.  
• The QTcF value > 500 ms is not confirmed.  
• Cabozantinib treatment has been interrupted through a minimum of 1 week following the retur n of the QTcF to ≤ 500 ms. 
• QT prolongation can be unequivocally associated with an event other than cabozantinib.  
• Cardiac evaluation confirms that symptoms are the consequence of QT interval 
prolongation.  
• Recurrence of QTcF prolongation after reinitiation  of study treatment at a reduced 
dose. 
• Administration and is treatable/has been resolved .  
Following reinitiation  of study treatment, ECGs must be repeated weekly for [ADDRESS_799690] be permanently discontinued if either  of the following applies:  
Electrolyte Disorder s: Serum electrolyte disorders including hyponatremia, hypokalemia, 
hypomagnesemia, and hypophosphatemia have been reported during treatment with cabozantinib, and serum electrolyte levels should be monitored frequently while receiving 
cabozantinib. Clinic ally relevant electrolyte disorders should be managed according to the 
dose modification guidelines. Standard clinical practice guidelines should be used for 
management of electrolyte disorders and may include oral or intravenous replacement.  
Endocrine Di sorders: Treatment -emergent elevation of thyroid -stimulating hormone (TSH) 
has been observed with cabozantinib treatment. Currently available data are insufficient to 
determine the mechanism of thyroid function test alterations and its clinical relevance. Management of thyroid dysfunction (e .g., symptomatic hypothyroidism) should follow 
accepted clinical practice guidelines.  
Short Title:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced Urothelial 
Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page 56 of 82 Angioedema: Angioedema should be managed according to standard practice. The subject 
should be observed until symptoms resolve, with particular attention to maintaining an open airway.  
7.2 Dose modification and toxicity management guidelines for pembrolizumab 
Dose modification and toxicity management for immune- related AEs associated with 
Pembrolizumab  
AEs associated with pembrolizumab exposure may represent an immunologic etiology. These immune- related AEs (irAEs) may occur shortly after the first dose or several months 
after the last dose of pembrolizumab treatment and may affect more than one body system simultaneously. Therefore, early recognition and initiation of treatment is critical to reduce complications . Based on existing clinical trial data, most irAEs were reversible and could be 
managed with interruptions of pembrolizumab, administration of corticosteroids and/or other supportive care. For suspected irAEs, ensure adequate evaluation to confirm etiology or exclude other causes. Additional procedures or tests such as bronchoscopy, endoscopy, skin biopsy may be included as part of the evaluation. Based on the severity of irAEs, withhold or permanently discontinue pembrolizumab and administer corticosteroids. Dose modification and toxicity management guidelines for irAEs associated with pembrolizumab  are provided 
in Table 7.9. 
Table 7.9: Dose modification and toxicity management guidelines for immune -related 
AEs associated with Pembrolizumab. 
General instructions:  
1. Corticosteroid taper should be initiated upon AE improving to Grade [ADDRESS_799691] dose or corticosteroids 
cannot be reduced to ≤ [ADDRESS_799692] followed by [CONTACT_440551]. Other immunosuppressive treatment should be initiated if irAEs cannot be controlled by 
[CONTACT_13216].  
Immune -
related 
AEs Toxicity 
grade or 
conditio
ns 
(CTCA
E v.5.0) Action 
taken to 
pembrolizu
mab  irAE management 
with corticosteroid 
and/or other 
therapi[INVESTIGATOR_44790] -up  
Pneumoniti
s  Grade 2  Withhold  • Administer 
corticosteroids 
(initial dose of 1 -
2mg/kg prednisone or equivalent) followed by [CONTACT_13217]  
 • Monitor subjects for signs and 
symptoms of pneumonitis  
• Evaluate subjects with suspected 
pneumonitis with radiographic 
imaging and initiate c orticosteroid 
treatment  
• Add prophylactic antibiotics for 
opportunistic infections  Grade 3 
or 4, or recurrent grade 2  Permanently 
discontinue  
Short Title:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced Urothelial 
Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page 57 of 82 Diarrhea / 
colitis  Grade 2 
or 3 Withhold  • Administer 
corticosteroids 
(initial dose of 1 -
2mg/kg prednisone or equivalent) 
followed by [CONTACT_13217]  
 • Monitor subjects for signs and 
symptoms of enterocolitis (i.e. , 
diarrhea, abdominal pain, blood or 
mucus in stool with or without 
fever) and of bowel perforation (i.e. , 
peritoneal signs and ileus).  
• Subjects with ≥ Grade 2 dia rrhea 
suspecting colitis should consider  GI 
consultation and performing endoscopy to rule out colitis.  
• Subjects with diarrhea/colitis should be advised to drink liberal quantities 
of clear fluids . If sufficient oral fluid 
intake is not feasible, fluid and  
electrolytes should be substituted via 
IV infusion.  Grade [ADDRESS_799693] / ALT 
elevation or 
Increased 
Bilirubin  Grade 2  Withhold  • Administer 
corticosteroids 
(initial dose of 0.5 - 
1mg/kg prednisone 
or equivalent) 
followed by [CONTACT_13217]  • Monitor with liver function tests 
(consider weekly or more frequently 
until liver enzyme value returned to 
baseline or is stable  
Grade 3 
or 4  Permanently 
discontinue  • Administer 
corticosteroids 
(initial dose of 1 -
2mg/kg prednisone 
or equivalent) 
followed  by [CONTACT_44878] 1 
diabetes 
mellitus 
(T1DM) or 
Hyperglyce
mia 
 Newly 
onset T1DM 
or  
Grade 3 
or 4 
hypergly
cemia 
associate
d with 
evidence 
of β-cell 
failure  Withhold  • Initiate insulin 
replacement 
therapy for subjects 
with T1DM  
• Administer anti -
hyperglycemic in subjects with 
hyperglycemia  
 • Monitor subjects for hyperglycemia or other signs and symptoms of 
diabetes.
 
Hypophysit
is Grade 2  Withhold  • Administer 
corticosteroids and 
initiate hormonal replacements as 
clinically 
indicated .  
 • Monitor for signs and symptoms of 
hypophysitis (including hypopi[INVESTIGATOR_19341])  
 Grade 3 
or 4  Withhold or 
permanently 
discontinue1  
Hyperthyro
idism  Grade 2  Continue  • Treat with non -
selective beta-blockers (e.g. propranolol) or 
thionamides as 
appropriate  • Monitor for signs and symptoms of 
thyroid disorders.  
 
Grade 3 
or 4  Withhold or  
Permanently discontinue
1 
Short Title:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced Urothelial 
Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page 58 of 82 Hypothyroi
dism  Grade 2 -
4 Continue  • Initiate thyroid 
replacement 
hormones (e.g. 
levothyroxine or 
liothyroinine) per 
standard of care  • Monitor for signs and symptoms of 
thyroid disorders.  
 
Serum 
Creatinine 
Increased  Grade 2  Withhold  • Administer 
corticosteroids 
(prednisone 1-
2mg/kg or 
equivalent) 
followed by [CONTACT_13217].  • Monitor changes of renal function  
 
Grade 3 
or 4  Permanently 
discontinue  
All Other 
immune -
related AEs  Grade 3, 
or intolerab
le/ 
persisten
t Grade 
2 Withhold  • Based on severity 
of AE administer 
corticosteroids  • Ensure adequate evaluation to 
confirm etiology or exclude other causes  
 
Grade 4 
or 
recurrent 
Grade 3  Permanently 
discontinue  
NOTES:  
1. Withhold or permanently discontinue pembrolizumab is at the discretion of the investigator or treating 
physician .  
2. For subjects with Grade 3 or 4 immune -related endocrinopathy where withhold of pembrolizumab is 
required, pembrolizumab may be resumed when AE resolves to ≤ Grade 2 and is controlled with 
hormonal replacement therapy or achieved metabolic control (in case of T1DM)  
Pembrolizumab may cause severe or life threatening infusion -reactions including severe 
hypersensitivity or anaphylaxis. Signs and symptoms usually develop during or shortly after 
drug infusion and generally resolve completely within 24 hours of c ompletion of infusion. 
Dose modification and toxicity management guidelines on pembrolizumab associated infusion reaction are provided in Table 7.10.  
Table  7.10:  Pembrolizumab Infusion Reaction Dose modification and Treatment 
Guidelines  
NCI CTCAE Grade  Treatment  Premedication at Subsequent 
Dosing  
Grade 1  
Mild reaction; infusion 
interruption not indicated; 
intervention not indicated  Increase monitoring of vital signs 
as medically indicated until the 
subject is deemed medically stable 
in the opi[INVESTIGATOR_871].  None 
Short Title:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced Urothelial 
Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page 59 of 82 Grade 2  
Requires therapy or infusion 
interruption but responds 
promptly to symptomatic treatment (e.g., 
antihistamines, NSAIDs, 
narcotics, IV fluids); 
prophylactic medications 
indicated for ≤24 hrs
 Stop Infusion.  
Additional appropri ate medical 
therapy may include but is not limited to:  
IV fluids  
 Antihistamines  
NSAIDs  
Acetaminophen  
Narcotics  
Increase monitoring of vital signs as medically indicated until the subject is deemed medically stable 
in the opi[INVESTIGATOR_871].  
If symptoms resolve within 1 hour 
of stoppi[INVESTIGATOR_13056], the 
infusion may be restarted at 50% 
of the original infusion rate (e.g. , 
from 100 mL/hr to 50 mL/hr) . 
Otherwise dosing will be held 
until symptoms resolve and the 
subject should be premedicated for the next scheduled dose.  
Subjects who develop Grade [ADDRESS_799694] may be premedicated 1.5h (± 
30 minutes) prior to infusion of 
pembrolizumab with:  
Diphe nhydramine 50 mg po (or 
equivalent dose of antihistamine).  
Acetaminophen 500- 1000 mg po (or 
equivalent dose of analgesic).  
Grades 3 or 4  
Grade 3:  
Prolonged (i.e., not rapi[INVESTIGATOR_38194]/or brief 
interruption of infusion); 
recurrence of symptoms 
following initial improvement; hospi[INVESTIGATOR_260711] (e.g., renal 
impairment, pulmonary 
infiltrates)  
Grade 4:  
Life-threatening; pressor or 
ventilatory support indicated
 Stop Infusion.  
Additional appropriate medical 
therapy may include but is not 
limited to:  
Epi[INVESTIGATOR_238]**  
IV fluids  
Antihistamines  
NSAIDs  
Acetaminophen  
Narcotics  
Oxygen  
Pressors  
Corticosteroids  
Increase monitoring of vital signs as medically indicated until the 
subject is deemed medically s table 
in the opi[INVESTIGATOR_871].  
Hospi[INVESTIGATOR_13021].  
**In cases of anaphylaxis, epi[INVESTIGATOR_13079].  
Subject is permanently discontinued from further study drug treatment.
 No subsequent dosing  
Short Title:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced Urothelial 
Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page 60 of 82 Appropriate resuscitation equipment should be available at the bedside and a physician readily available during the period 
of drug administration.  
For further information, please refer to the Common Terminology Criteria for Adverse Events v .5.0 (CTCAE) at 
http://ctep. cancer.gov  
Other allowed dose interruption for pembrolizumab  
Pembrolizumab may be interrupted for situations other than treatment -related AEs such as 
medical / surgical events or logistical reasons not related to study therapy. Subjects should be 
placed back on study therapy within 3 weeks of the scheduled interruption, unless otherwise discussed with the study sponsor (principal investigator) . The reason for interruption should 
be documented in the patient's study record. Patients with a planned interrup tion may 
continue on the study with monotherapy of the other agent. Patients may also continue on the 
study with a planned permanent discontinuation of one of the study medications.  
7.[ADDRESS_799695] azoospermia (whether due to having had a vasectomy or due to an underlying medical 
condition).  
Female subjects will be considered of non- reproductive potenti al if they are either:  
(1) postmenopausal (defined as at least 12 months with no menses without an alternative 
medical cause; in women < 45 years of age a high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a post -menopausal state in women not 
using hormonal contraception or hormonal replacement therapy. In the absence of 12 months of amenorrhea, a single FSH measurement is insufficient.);  
OR  
(2) have had a hysterectomy and/or bilateral oophorectomy, bilateral  salpi[INVESTIGATOR_176715]/occlusion, at least 6 weeks prior to screening;  
OR  
(3) has a congenital or acquired condition that prevents childbearing.  
Female and male subjects of reproductive potential must agree to avoid becoming pregnant 
or impregnating a partner, respectively, while receiving study drug and for [ADDRESS_799696] dose of study drug by [CONTACT_139649]:  
(1) practice abstinence
† from heterosexual activity;  
OR  
(2) use (or have their partner use) acceptable contraception during heterosexual activity .  
Acceptable methods of contraception are‡: 
Single method (one of the following is acceptable):  
• Intrauterine device (IUD)  
Short Title:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced Urothelial 
Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page 61 of 82 • Vasectomy of a female subject’s male partner  
• Contraceptive rod implanted into the skin 
Combination method (requires use of two of the following):  
• Diaphragm with spermicide (cannot be used in conjunction with cervical 
cap/spermicide)  
• Cervical cap with spermicide (nulliparous women only)   
• Contraceptive sponge (nulliparous women only)  
• Male condom or female condom (cannot be used together)  
• Hormonal contraceptive: oral contraceptive pi[INVESTIGATOR_4382] (estrogen/progestin pi[INVESTIGATOR_64870] -
only pi[INVESTIGATOR_4382]), contraceptive skin patch, vaginal contraceptive ring, or subcutaneous 
contraceptive injection  
†Abstinence (relative to heterosexual activity) can be used as the sole method of contraception if it is consistently employed as the subject’s preferred and usual lifestyle and if considered acceptable by [CONTACT_176742]/IRBs . Periodic abstinence 
(e.g., calendar, ovulation, sympto- thermal, post -ovulation methods, etc.) and withdrawal are 
not acceptable methods of contraception.  
‡If a contraceptive method listed above is restricted by [CONTACT_427]/guidelines, then it does not qualify as an accepta ble method of contraception for subjects participating at sites in 
this country/region.  
Subjects should be informed that taking the study medication may involve unknown risks to the fetus (unborn baby) if pregnancy were to occur during the study . In order to participate in 
the study subjects of childbearing potential must adhere to the contraception requirement 
(described above) from the day of study medication initiation (or 14 days prior to the initiation of study medication for oral contraception) throug hout the study period up to [ADDRESS_799697] should not be entered into the study . 
7.4 Supportive Care  
All supportive measures consistent with optimal patient care will be given throughout the study.  
 
Short Title:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced Urothelial Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page 62 of 82 8 STUDY CALENDAR  
1 cycle = 3 w eeks ± 3 days  
Examination  Pre-
screening23 Screening1 C1, 5, 9…  
Day 12 C2, 6, 10…  
Day 1  C3, 7, 11…  
Day 1  C4, 8, 12…  
Day1  End of 
Treatment20 Follow -up21 
Informed consent  X X             
Medical history   X             
Eligibility criteria  X X             
Vital signs, weight   X X X X X X   
Height   X             
Physical examination3  X X X X X X   
ECOG performance status   X X X X X X   
Viral Hepatitis Screening4  X             
Smoking History   X             
Hematology5  X X X X X X   
Chemistry6  X X X X X X   
LDH, Lipase, Lipid Panel, GGT7  X    X X   
BNP22  X    X X  
Urinalysis8  X X X  X  X X   
Coagulation9  X       X X    
Thyroid Function Test10  X       X X    
Pregnancy test11  X    X   X     
ECG12  X      X     
Concomitant Medications   X   
Adverse Event Assessment     X   
CT Scans (c, a, p)13  X       X13 X X21 
Bone Scans14  X X      X X  
Optional Tissue for Correlative Studies15 X (X)15      X    
Optional Blood for Correlative Studies16   X X X X  X   
Optional Stool for Correlative Studies17   X X X X  X   
Optional Stool Questionnaire to 
accompany Optional Stool sample 
collection for Correlative Studies17  
 X X X X  X  
Cabozantinib18    X X X X     
Pembrolizumab19    X X X X     
Survival Follow Up        X21 
Short Title:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced Urothelial Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page [ADDRESS_799698] be completed within 28 days prior to C1D1  ALL Pre -study/Screening procedures should be completed within 4 weeks of study 
enrollment - with the exception of laboratory tests which need to be completed within 14 days  prior to study treatment . 
2. Labs on C1D 1 do not need to be repeated if conducted wit hin 14 day s of start of treatment  
3. Physical Exam including oral exam ination  
4. Hepatitis screening  will be performed at screening if clinically ind icated.  
5. Hematology includes CBC with differential and platelets (must be completed within 2 weeks prior to study  enrollment) . 
6. Chemistry includes Albumin, Alkaline Phosphatase, Aspartate Aminotransferase, Alanine Aminotransferase, Total Bilirubin, Calcium, Carbon Dioxide, Creatinine, 
Chloride, Glucose, Potassium, Protein, Sodium, Urea Nitrogen,  phosphorus and magnesi um (must be completed within 14 days  prior to study enrollment  at 
screening ) 
7. Additional Labs : Lactate Dehydrogenase, Lipase, Lipid Panel, Gamma Glutamyl Transferase, and should be collected at baseline and at every 4th cycle.  
8. Urinalysis  including urine protein/creatinine ratio on day 1 of each cycle.  Both spot protein/creatinine and the 24 protein/creatinine evaluations are acceptable.  
9. Coagulation  labs to be collected: PT/INR, APTT . Coagulation panel will only be required at EOT if patients are on active  anticoagulant therapy and require 
monitoring.  
10. Free T4 , Free T3  and TSH must be performed at baseline ant at least every 4th cycle  during treatment  
11. Pregnancy test (serum or urine - if urine is positive it must be confirmed with serum test) must be done at screening for all women of childbearing potential a nd every 
even cycle (2,4,6 … etc.) during treatment (must be completed within 72hr prior to study enrollment)  
12. ECG  should be collected at screening  (see section 9 for QTcF eligibility details at screening)  and at every 4th cycle .  
13. CT scans of chest, abdomen and pelvis will be repeated every 4th cycle  during treatment  within 1 week prior to the corresponding cycle  (e.g., prior to cycle 5, 9, 13...  
etc.). However, if the study treatment is delayed, scans can be delayed to correspond to the treatment schedule, and this will not be a deviation. CT scans will be done 
at the end of treatment visit only if patient has come off for reasons other than progression . Use of contrast according to institutional practice i s recommended but not 
required .  
14. Bone Scans  if clinically indicated for evaluation of bone metastatic disease 
15. For participants who opt in to the optional tissue collection, t issue may be coll ected at pre- screening from an  urothelial carcinoma diagnostic procedure  (soft tissue 
biopsy  or TURBT) or during screening from a soft tissue biopsy (only for patients who do not sign the pre -screening ICF). Subjects are also offered the option of a 
fresh soft -tissue biopsy  or TURB T again prior to treatment at cycle 4  or after . See Section 14 for details.  
16. For participants who opt in to the optional blood collection, blood may be collected  on C 1D1, C2D1 , C4D1, C7D1, C13D1, and at end of treatment . See Section 14 
for details . 
17. For participants who opt in to the optional stool collection, s tool may be collected  and stool questionnaire administered within 3 days prior to treatment on C1D1, 
C2D1, C4D1, C7D1, C13D1,  and at end of treatment. See Section 14 for details.  
18. Cabozantinib at dose specified in dose escalation and specified in section 6 .2. Subjects will complete dosing diary for each cycle (Appendix I)  
19. Pembrolizumab 200 mg IV q3weeks  
20. End of treatment v isit should occur within 28 (± 14) days after subject completes study treatment  
21. Follow up visits : Patients will be followed via telephone contact [CONTACT_603879] 6 months after completing study  treatment . Patients removed 
from therapy without evidence of progression will undergo radiological examination eve ry 12 (±1) weeks or earlier,  if clinically warranted.  
22. B type Natriuretic Peptide should be collected  
23. Pre-screening ICF and eligibility review must be completed with 4 weeks prior to urothelial carcinoma diagnostic procedure ( soft tissue  biopsy or TURBT ).  
Short Title:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced 
Urothelial Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page 64 of 82 9 STUDY PROCEDURES  
9.1 Pre-Screening  
Pre-screening informed consent 
Pre-screening eligibility review  
Optional tissue collection (at the time of the standard of care urothelial carcinoma 
diagnostic procedure) within 4 weeks of study registration  
9.2 Screening  
Informed Consent 
Physical exam  
Vital Signs (incl. height/weight)  
Review of medical history/baseline symptoms /smoking history/concomitant 
medications  
ECOG Performance status  
Labs:   
• CBC w/diff  
• CMP – Albumin, Alkaline Phosphatase, Aspar tate Aminotransferase, Alanine 
Aminotransferase, Total Bilirubin, Calcium, Carbon Dioxide, Creatinine, 
Chloride, Glucose, Potassium, Protein, Sodium, Urea Nitrogen , phosphorous 
and magnesium.  
• Additional Labs: LDH, Lipase, Lipid Pane l, Gamma Glutamyl Trans ferase, B -
type Natriuretic peptide  
• Coag ulation  – PT /INR, APTT  
• Thyroid function – TSH, Free T4 , Free T3  
• Serum pregnancy test (for women of childbearing potential) 
• Urinalysis including urine protein creatinine ratio  
• Viral Hepatitis Screening (if clinically indicated) 
ECG : If a single ECG shows a QTcF with an absolute value > [ADDRESS_799699]/abdomen/pelvis 
Bone Scans if clinically indicate d 
Optional Tissue Collection for correlatives see section 14 
9.3 On-Treatment Evaluations 
Physical Exam  – at each cycle  
Short Title:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced 
Urothelial Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page 65 of 82 ECOG Performance Status  – at each cycle  
Vital Signs (Incl. weight) – at each cycle  
Labs: (do not need to be repeated if screening labs performed within 14 days of 
C1D1)  
• CBC w/diff  – at each cycle  
• CMP – Albumin, Alkaline Phosphatase, Aspartate Aminotransferase, Alanine Aminotransferase, Total Bilirubin, Calcium, Carbon Dioxide, Creatinine, Chloride, Glucose, Potassium, Protein, Sodium, Urea Nitrogen , phosphorous 
and magnesium. – at each cycle  
• Additional Labs: LDH, Lipase, Lipid Panel, Gamma Glutamyl Transferase, N-type Natriuretic peptide – at eve ry fourth cycle  (4, 8, 12…)  
• Coag ulation  – PT /INR, APTT – at every fourth cycle (4, 8, 12…)  
• Thyroid function – TSH, Free T4 , Free T3  – at every fourth cycle (4, 8, 12…)  
• Serum pregnancy test (for women of childbearing potential)  at every even 
cycle  (2, 4, 6… )  
• Urinalysis including urine protein creatinine ratio – at every cycle  
ECG  – at every fourth cycle (4, 8, 12…)  
Safety assessment - Monitoring and recording all adverse events and serious adverse 
events using the CTCAE version 5.0 – at each cycle 
Review of concomitant medications  – at each cycle  
CT scans  of the chest/abdomen/pelvis and response assessment by [CONTACT_34443]  v1.1 to be 
repeated every 4
th cycle . However, if the study treatment is delayed, scans can be 
delayed to correspond to the treatment schedule, and this will not be a deviation.   
Bone Scans if clinically indicate d 
Optional Tissue Collection for correlatives at cycle 4 , or after,  see section 14  
Optional Blood and Stool Collection  and administration of Stool Questionnaire  for 
correlatives – at C1D1 , C2D1, C4D1, C7D1, C13D1 see section 14  
Treatment with 200mg pembrolizumab per section 6.3 Treatment with appropriate dose of cabozantinib – review of patient dosing diary  per 
section 6.2  
9.4 End of Treatment Assessments (completed 28 days ± 14 days after 
completion of treatment  
Physical exam  
Vital Signs   
Concomitant medication collection  
ECOG Performance status  
Short Title:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced 
Urothelial Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page 66 of 82 Labs:   
• CBC w/diff  
• CMP – Albumin, Alkaline Phosphatase, Aspartate Aminotransferase, Alanine 
Aminotransferase, Total Bilirubin, Calcium, Carbon Dioxide, Creatinine, Chloride, Glucose, Potassium, Protein, Sodium, Urea Nitrogen . Phosphorus  
and magnesium  
• Additional Labs: LDH, L ipase, Lipid Panel, Gamma Glutamyl Transferase, B -
type Natriuretic peptide  
• Thyroid function – TSH, Free T4, Free T3 
• PT/INR, aPTT if patients are on active anticoagulant therapy and require monitoring  
• B-type Natriuretic peptide  
• Urinalysis including urine pr otein creatinine ratio  
Optional Blood and Stool Collection  and administration of Stool Questionnaire  for 
correlatives see section [ADDRESS_799700]/abdomen/pelvis and response assessment by [CONTACT_34443]  v1.[ADDRESS_799701] criteria30 will be 
used as an exploratory measurement of efficacy which may be performed retrospectively.   
Short Title:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced 
Urothelial Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page [ADDRESS_799702] be confirmed as follows:  
• Partial or complete responses (PR or CR, respectively) must be confirmed by 
[CONTACT_603880] [ADDRESS_799703] assessment showing PR/CR.  
• Stable disease (SD), measurements must have met the SD criteria at least once after study entry at a minimum interval of  9 weeks.  
• Patients with progressive disease (PD) who are receiving clinical benefit in the opi[INVESTIGATOR_603851]. Repeat imaging to confirm PD should be performed according to t he schedule of events ([ADDRESS_799704] 
evidence of progression) or sooner at the discretion of the investigator but at least [ADDRESS_799705] evidence of progression.   
• Patients who are experiencing unequivocal RECIST v1.[ADDRESS_799706] response observed until progression/recurrence and is dete rmined as indicated in the table below:  
Target Lesions  Non-Target 
Lesions  
 Evaluation of New 
Lesions  Best Overall 
Response  
CR CR No CR 
CR SD No PR 
PR Non-PD No PR 
SD Non-PD No SD 
PD Any Yes or No  PD 
Any PD Yes or No  PD 
Any Any Yes PD 
10.[ADDRESS_799707] one dose of any of the two agents are evaluable for safety.  
Physical Examination 
Complete and symptom- directed physical examinations  will be performed by a 
licensed ph ysician (or physician’s assistant or nurse practitioner).  
Vital Signs  
Short Title:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced 
Urothelial Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page 68 of 82 Vital signs (blood pressure, respi[INVESTIGATOR_697], pulse rate and temperature) will be 
obtained.  
Safety Laboratory Determinations  
Laboratory evaluations will be performed as noted in the f low chart.  
[ADDRESS_799708] been performed. One study identified 
an objective response rate of 36%, with a median progression- free survival of only 
4.8 months in 56 treated patients .23 A second study of 60 patients noted an objective 
response rate of 38.4%, with a media n progression- free survival of 7.6 months . 24 It 
has also been reported a 26% ORR in patient treated with pembrolizumab with 
locally advanced or metastatic urothelial cancer25. ORR will be analyzed 
descriptively. The proportion of objective responses will be reported and a  95% one -
sided exact binomial confidence interval (Clopper -Pearson) will be calculated for 
ORR. With 35 evaluable subjects the lower bound of the 95% confidence interval will extend no more than 26% from the observed proportion. If there a re 17 or more 
objective responses in 35 patients the confidence interval will exclude 32%. Adding another 10% for  unevaluable  patients that may be enrolled, a total of up to 39 patients 
will be enrolled.  
11.2 Secondary Objectives  and Endpoints  
The secondary objectives are to evaluate progression free survival at 6 months and overall survival of  pembrolizumab +  cabozantinib in subjects with  UC. Kaplan -Meier 
methods and associated confidence intervals will be used to analyze PFS  and OS . 
Subjects w ill be evaluated for survival for [ADDRESS_799709] binomial confidence interval. As an additional 
secondary analysis, stratified Kaplan -Meier methodology will be used to associate risk 
group (based on performance status and visceral metastasis) with PFS.  
11.[ADDRESS_799710] not yet 
been finalized.  Once a decision has bee n made, a statistical plan will be written  and 
an amendment to the protocol will be made . 
Short Title:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced 
Urothelial Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page [ADDRESS_799711] not begin protocol treatment prior to registration.  
Treatment should start within five working days after registration.  
To register eligible patients on study, complete a Clinical Trials Office Patient Registration Form and subm it to: [EMAIL_6714]
.  
13 DATA SUBMISSION SCHEDULE  
The Case Report Forms (CRFs) are a set of (electronic or paper) forms for each patient that provides a record of the data generated accordi ng to the protocol. CRF’s should be 
created prior to the study being initiated and updated (if applicable) when amendments to the protocol are IRB approved. Data capture should be restricted to endpoints and relevant patient information required for planned manuscripts . These forms will be 
completed on an on-going basis during the study. The medical records will be source of 
verification of the data . During the study, the CRFs will be monitored for completeness, 
accuracy, legibility and attention to detail by a member of the Research Compliance Office.  The CRFs will be completed by [CONTACT_29517] a member of the study team as 
listed on the Delegation of Duties Log. The data will be reviewed no less than annually by [CONTACT_140308]. The Investigator will allow the Data and Safety Monitoring Committee or Research Compliance Office personnel access to the patient source documents, clinical supplies dispensing and storage area, and study documentation for the above-mentioned purpose. The Investigator further agrees to assist 
the site visitors in their activities .  
14 SPECIAL INSTRUCTIONS   
14.1 Correlative Studies  
Correlative studies may include but are not limited to analysis that identify the mechanisms of response and resistance to immunotherapy, at the cellular and molecular levels . 
 Collection of Tumor Tissue 
Participants who opt in to the optional tissue collection, t issue may  be collected at 
pre-screening from an urothelial carcinoma diagnostic procedure (soft tissue biopsy 
or TURBT) or during screening from a soft tissue biopsy (only for patients who do not sign the pre-screening ICF). Subjects are also offered the option of a fresh soft-tissue biopsy or TURBT again prior to treatment at cycle 4  or after. Up to ten sections 
will be collected during the TURBT  and up to six cores will be obtained at the time of 
soft tissue biopsy. These tissues will be used to establish a biomarker panel predictive of treatment effi cacy which will be validated in future clinical trials.  
Short Title:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced 
Urothelial Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page 70 of 82 Testing may include, but is not limited to:  
• Multiomics platforms  
• Immunohistochemistry  
• Flow cytometry   
• Ex vivo treatment  to predict treatment efficacy  
Instructions for processing and analysis will be detailed in the lab manual.  
 Collection of Blood for Correlative Analysis  
Participants who opt in to the optional blood collection , up to 36mL of b lood may be 
collected  on C1D1, C2D1, C4D1, C7D1, C13D1, and at end of treatment.  
These samples will be used to test for biomarkers of disease response and prediction 
of treatment effect . Testing may include, but is not limited to:  
• C-reactive protein (CRP)  
• Neutrophil to Lymphocyte ratio  
• Hemoglobin  
• Cytokine/ chemokine/interferon assays  
• Flow cytometry  
• Mass cytom etry  
• T-cell kinetics  
• Genome analysis  
Specimen collection and processing instructions can be found in the lab manual. 
 Collection of Stool S amples for Correlative Analysis  
Collection of stool samples  and administration of Stool Questionnaire  may  occur 
prior to treatment on cycles 1, 2, 4, 7, 13, and at the end of treatment . Stool collection 
kits will be given to subjects at the clinic visit preceding the collection time point and they will be instructed to collect the sample within 3 days prior to the t ime points  
noted above  and answer the questionnaire provided in the stool kit  (Appendix B) .  
These samples will be used to determine a predictive microbiome signature [CONTACT_603891].  
Testing may include, but is not limited to:  
• 16S ribosomal RNA sequencing  
• Cultivation of microbes  
• Shotgun metagenomics  
Specimen collection  and storage instructions can be found in the lab manual  and the 
patient stool collection instructions.  
Short Title:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced 
Urothelial Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page [ADDRESS_799712] written and dated approval/favorable 
opi[INVESTIGATOR_5698]/IEC for the protocol, consent form, subject recruitment materials (e.g., advertisements), and any other applicable patient -facing documents. The 
investigator should also provide the IRB/IEC with a copy of the Investigator Brochure 
or product labeling information. 
The investigator or designee should provide the IRB/IEC with reports, updates and 
other information (e .g., expedited safety reports, amendments, and administrative 
letters) according to regulatory requirements or institution  procedures.  
 
15.3  Data and Safety Monitoring Plan  
A Data and Safety Monitoring Committee (DSMC) is established at Huntsman 
Cancer Institute (HCI) to ensure  the well -being of patients enrolled on Investigator 
Initiated Trials that do not have an outside monit oring review. The roles and 
responsibilities of the DSMC are set forth in the NCI -approved Data and Safety 
Monitoring (DSM) plan. The activities of the committee include reviewing adverse 
events (including SAEs), deviations, important medical events, signi ficant revisions 
or amendments to the protocol, and approving cohort/dose escalations. If the DSMC and/or the PI [INVESTIGATOR_447143], the study will be stopped and will not be resumed until the issues are resolved. The DSMC also re views and 
approves audit reports generated by [CONTACT_349129].  
This is a Phase II , multicenter, study  classified as high  risk per the NCI -approved 
DSM plan.  
Each high  risk study may be assigned a physician member of the DSMC as medical 
monitor, or in rare cases, an external medical monitor. The medical monitor will be 
notified of all serious adverse  events (SAEs). Approval of the medical monitor is 
required for all dos e escalations.  SAEs occurring in patients treated at HCI or its 
affiliates will also be reviewed by [CONTACT_603881]. The full committee will also review all toxicities for patients on treatment and within [ADDRESS_799713] patient is enrolled and every three months thereafter duri ng active enrollment. 
The RCO monitor will review the study status and summarize enrollment, toxicities, SAEs, dose escalation, statistical endpoints (e.g., stoppi[INVESTIGATOR_004]), deviations, etc. for the full DSMC membership at the regularly scheduled meetings.  Amendments that 
Short Title:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced 
Urothelial Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page [ADDRESS_799714] 6 patients enroll and receive treatment. During this stage, the decision to continue enrollment will be made by [CONTACT_603869] (DSMC). When all [ADDRESS_799715] dose of pembrolizumab and cabozantinib, all available safety data will be considered in a decision to continue enrollment.  
15.4 Adverse Events / Serious Adverse Events  
This study will utilize the CTCAE (NCI Co mmon Terminology Criteria for Adverse 
Events) Version 5.0 for AE and SAE reporting .  
 Adverse Events (AE)  
An adverse event is the appearance or worsening of any undesirable sign, symptom, or medical condition occurring after starting the study drug even if the event is not 
considered to be related to study drug. For the purposes of this study, the terms 
toxicity and adverse event are used interchangeably. Medical conditions/diseases present before starting study drug are only considered adverse events if the y worsen 
after starting study drug. Abnormal laboratory values or test results constitute adverse events only if they induce clinical signs or symptoms, are considered clinically significant, or require therapy.  
The collection of adverse events will begin after the signature [CONTACT_603892] [ADDRESS_799716] or other means, will be collected and recorded and followed as appropriate. 
Adverse event s should be evaluated to determine:  
1. The severity grade based on CTCAE v .5.0 (grade 1 -5) 
2. Its relationship to the study drug(s) (definite, probable, possible, unlikely, not 
related ). 
3. Its duration (start and end dates or if continuing at final exam)  
4. Action taken (no action taken; study drug dosage adjusted/temporarily 
interrupted; study drug permane ntly discontinued due to this adverse event; 
concomitant medication taken; non- drug therapy given; 
hospi[INVESTIGATOR_059]/prolonged hospi[INVESTIGATOR_059])  
5. Whether it constitutes an SAE  
Short Title:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced 
Urothelial Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page 73 of 82 All adverse events will be treated appropriately. Such treatment may include changes  
in study drug treatment as listed in the dose modification section of this protocol (see 
section 7 for guidance). Once an adverse event is detected, it should be followed until its resolution, and assessment should be made at each visit (or more frequentl y, if 
necessary) of any changes in severity, the suspected relationship to the study drug, the interventions required to treat it, and the outcome.  
Information about common side effects already known about the investigational  drug s 
is described in the Drug  Information (section 3) and (the m ost recent Investigator 
Brochures ). This information will be included in the patient informed consent and 
will be discussed with the patient during the study as needed.  
All adverse events will be immediately recorded in t he patient research chart.  
 Serious Adverse Event (SAE)  
Information about all serious adverse events will be collected and recorded. A serious adverse event is an undesirable sign, symptom or medical condition which:  
• Is fatal or life -threatening  
• Results in  persistent or significant disability/incapacity  
• Is medically significant, i.e., defined as an event that jeopardizes the patient or 
may require medical or surgical intervention to prevent one of the outcomes listed above  
• Causes congenital anomaly or birth defect  
• Requires inpatient hospi[INVESTIGATOR_1081], 
unless hospi[INVESTIGATOR_062]:  
o Routine treatment or monitoring of the studied indication, not associated with 
any deterioration in condition (procedures such as central  line placements, 
paracentesis, pain control)  
o Elective or pre -planned treatment for a pre -existing condition that is unrelated 
to the indication under study and has not worsened since the start of study drug 
o Treatment on an emergency outpatient basis for a n event not fulfilling any of 
the definitions of a SAE given above and not resulting in hospi[INVESTIGATOR_063] 
o Social reasons and respi[INVESTIGATOR_447144]’s general condition 
Serious adverse event collection will begin af ter the signature [CONTACT_603892] [ADDRESS_799717] be reported.  
Short Title:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced 
Urothelial Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page [ADDRESS_799718] be reported to the DSMC, the FDA, the IRB, and Exelixis  according to the 
requirements  described below:  
A MedWatch 3500A form must be completed and submitted to  [EMAIL_11517]
 
as soon as possible, but no later than [ADDRESS_799719] knowledge or notification of event. Medwatch 3500A form can be downloaded from the FDA website. 
DSMC Notifications:  
An HCI Research Compliance Officer (RCO) will pr ocess and submit the MedWatch 
form to the proper DSMC member as necessary for this study.  
The RCO will summarize and present all reported SAEs according to the Data and 
Safety Monitoring Plan at the monthly DSMC meeting.  
FDA Notifications: 
Adverse events occurring during the course of a clinical study that meet the following 
criteria will be promptly reported to the FDA:  
• Serious 
• Unexpected  
• Definitely, Probably or Possibly Related to the investigational drug 
Fatal or life -threatening events that meet the cr iteria above will be reported within [ADDRESS_799720] knowledge of the event by [CONTACT_093]; followed by [CONTACT_185548] a report as possible within 8 additional calendar days. 
• All other events that meet the criteria above will be reported within [ADDRESS_799721] knowledge of the event by [CONTACT_093]. 
• The RCO will review the MedWatch report for completeness, accuracy and applicability to the regulatory reporting requirements.  
• The RCO will ensure the complete, accurate and timely reporting of the event to the FDA.  
• The Regulatory Coordinator will submit the report as an amendment to the 
IND application. 
• All other adverse events and safety information not requiring expedited 
reporting that occur or are collected during the cours e of the study will be 
summarized and reported to the FDA through the IND Annual Report. 
Short Title:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced 
Urothelial Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page 75 of 82 IRB Notification:  
Events meeting the University of Utah IRB  or local IRB  reporting requirements will be 
submitted  per local guidelines. 
Drug Manufacturer  Notifications : 
All SAEs that are assessed by [CONTACT_978] [INVESTIGATOR_603852]/lactation reports regardless of outcome must be sent to Exelixis within one (1) business day of the PI’s knowledge of the event. The reports must be sent to [EMAIL_131] or fax [ADDRESS_799722], 
including the pregnancy of a male subjects’ female partner as an SAE. Pregnancies or lactation that occurs during the course of the trial or with [ADDRESS_799723] be followed to the completion/termination of the pregnancy. Pregnancy outcomes of spontaneous abortion, missed abortion, fetal 
death, intrauterine death, miscarriage and stillbirth must be reported as serious events.  
15.7 Medication Errors/Overdose 
Any overdose, or study drug administration error that results in an AE, even if it does 
not meet the defin ition of serious, requires reporting within one (1) business day to 
Exelixis.  
15.8 Protocol Amendments  
Protocol modifications (including protocol amendments) may be made and will be prepared, reviewed, and approved by [CONTACT_603882]. Protocol modifications or amendments must be reviewed and approved by [CONTACT_603883].  Any amendments or administrative changes  to an IRB approved 
protocol will not be initiated without submission of an amendment for IRB review and approval.  
These requirements for approval will in no way prevent any immediate action 
from being taken by [CONTACT_349133].  
Any amendments to the protocol that significantly affect the safety of subjects, 
scope of the investigation, or the scientific quality of the study are required to 
submit the amendment for FDA review. 
Short Title:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced 
Urothelial Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page 76 of 82 15.9 Protocol Deviations 
A protocol deviation (or violation) is any departure from the defined procedures and 
treatment p lans as outlined in the protocol version submitted and previously approved 
by [CONTACT_1201]. Protocol deviations have the potential to place participants at risk and can 
also undermine the scientific integrity of the study thus jeopardizing the justification 
for the research . Protocol deviations are unplanned and unintentional events.  
Because some protocol deviations pose no conceivable threat to participant safety or 
scientific integrity, reporting is left to the discretion of the PI [INVESTIGATOR_215442]. The IRB requires the prompt reporting  of protocol deviations 
which are:  
• Exceptions to eligibility criteria.  
• Intended to eliminate apparent immediate hazard to a research participant or  
• Harmful (caused harm to participants or others, or pl ace them at increased risk 
of harm - including physical, psychological, economic, or social harm), or  
• Possible serious or continued noncompliance  
15.[ADDRESS_799724] . (21 CFR 312.33).  
15.11 Clinical Trials Data Bank  
The study will be registered on http://clinicaltrials.gov  and the NCI CTRP (Clinical 
Trials Reporting Program) by [CONTACT_154464].  
15.[ADDRESS_799725] Keepi[INVESTIGATOR_349112] 21 CFR 312.57, Investigator records shall be maintained for a period of 2 years following the date a marketing application is approved; or, if no application is filed or the application is not approved, until [ADDRESS_799726] keepi[INVESTIGATOR_603853] .  
16 PUBLICATIONS OF DATA 
The Principal Investigator [INVESTIGATOR_603854]; provided that the PI [INVESTIGATOR_603855] a copy of any proposed publication or release in accordance with the clinical trial agreement.  
  
Short Title:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced 
Urothelial Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page 77 of 82 17 BIBLIOGRAPHY  
1. Sonpavde G, Watson D, Tourtellott M, et al. Administration of Cisplatin -based 
chemotherapy for advanced urothelial carcinoma in the community. Clin Genitourin 
Cancer . Mar: 10:1- 5 
2. Chen GJ GM, Latini D, Sonpavde G. Proportion of elderly patients with advanced bladder cancer receiving cisplatin -based chemotherapy: A large Medicare database 
study. Genitourinary Cancer Symposium 2013, February 14- 16, Orlando, [LOCATION_012], 
abstract 276.  
3. Galsky MD, Chen GJ, Oh WK, et al. Comparative effectiveness of cisplat in-based 
and carboplatin- based chemotherapy for treatment of advanced urothelial carcinoma. 
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2011 May 4:  
4. Cheng HL, Trink B, Tzai TS, et al. Overexpression of c -met as a prognostic indicator 
for transitional cell carcinoma of the urinary bladder: a comparison with p53 nuclear accumulation. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002 Mar 15: 20:1544- 50 
5. Yeh CY,  Shin SM, Yeh HH, et al. Transcriptional activation of the Axl and PDGFR -
alpha by c- Met through a ras - and Src -independent mechanism in human bladder 
cancer. BMC Cancer. 11:[ADDRESS_799727] of the orally available MET inh ibitor PF -
2341066 on tumor burden and metastasis in an orthotopic xenograft model of bladder cancer. J Clin Oncol 29: 2011 (suppl 7; abstr 263)  
7. Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent 
MA, Petrylak DP, Choueiri T K, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine 
S, Sternberg CN, Mai Y, Poehlein CH, Perini RF, Bajorin DF; KEYNOTE -045 
Investigators. Pembrolizumab as Second- Line Therapy for Advanced Urothelial 
Carcinoma N Engl J Med. 2017 Mar 16;376(11):1015- 1026. doi: 
10.1056/NEJMoa1613683. Epub [ADDRESS_799728] C, Gordon MS, Sharma S, Rafii S, Wainberg ZA, Luke J, Curiel TJ, Colon-Otero G, Hamid O, Sanborn RE, O'Donnell PH, Drakaki A, Tan W, Kurland JF, Rebelatto MC, Jin X, Blake -Haskins JA, Gupta A, Segal  NH. J Clin Oncol. Safety 
and Efficacy of Durvalumab (MEDI4736), an Anti -Programmed Cell Death Ligand -1 
Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer.2016 Sep 10;34(26):3119- 25. doi: 10.1200/JCO.2016.67.9761. Epub 2016 Jun 
6. 
9. Rosenberg JE, Hoffman- Censits J, Powles T, van der Heijden MS, Balar AV, Necchi 
A, Dawson N, O'Donnell PH, Balmanoukian A, Loriot Y, Srinivas S, Retz MM, Grivas P, Joseph RW, Galsky MD, Fleming MT, Petrylak DP, Perez -Gracia JL, 
Burris HA, Castellan o D, Canil C, Bellmunt J, Bajorin D, Nickles D, Bourgon R, 
Frampton GM, Cui N, Mariathasan S, Abidoye O, Fine GD, Dreicer R. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with pla tinum -based chemotherapy: a single -arm, 
multicentre, phase 2 trial.Lancet. 2016 May 7;387([ZIP_CODE]):1909- 20. doi: 
10.1016/S0140- 6736(16)[ZIP_CODE]- 4. Epub 2016 Mar 4. 
Short Title:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced 
Urothelial Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page 78 of 82 10. Sharma P, Retz M, Siefker -Radtke A, Baron A, Necchi A, Bedke J, Plimack ER, 
Vaena D, Grimm MO , Bracarda S, Arranz JÁ, Pal S, Ohyama C, Saci A, Qu X, 
Lambert A, Krishnan S, Azrilevich A, Galsky MD. Nivolumab in metastatic 
urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single -
arm, phase 2 trial.Lancet Oncol. 2017 Mar;18( 3):312- 322. doi: 10.1016/S1470-
2045(17)[ZIP_CODE]- 7. Epub 2017 Jan 26.  
11. Balar A, Bellmunt J, O’Donnell PH, et al. Pembrolizumab (pembro) as first -line 
therapy for advanced/unresectable or metastatic urothelial cancer: Preliminary results from the phase II KE YNOTE -052 study. Presented at: 2016 ESMO Congress; 
October 7 -11, 2016; Copenhagen, Denmark. Abstract LBA32.  
12. Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, Loriot Y, 
Necchi A, Hoffman -Censits J, Perez -Gracia JL, Dawson NA, van der  Heijden MS, 
Dreicer R, Srinivas S, Retz MM, Joseph RW, Drakaki A, Vaishampayan UN, Sridhar SS, Quinn DI, Durán I, Shaffer DR, Eigl BJ, Grivas PD, Yu EY, Li S, Kadel EE 3rd, Boyd Z, Bourgon R, Hegde PS, Mariathasan S, Thåström A, Abidoye OO, Fine GD, Bajor in DF; IMvigor210 Study Group. Atezolizumab as first -line treatment in 
cisplatin -ineligible patients with locally advanced and metastatic urothelial 
carcinoma: a single- arm, multicentre, phase 2 trial. Lancet. 2017 Jan 
7;389([ZIP_CODE]):67- 76. doi: 10.1016/S0140- 6736(16)[ZIP_CODE]- 2. Epub 2016 Dec 8. 
13. Du Four, S., et al., Axitinib increases the infiltration of immune cells and reduces the 
suppressive capacity of monocytic MDSCs in an intracranial mouse melanoma model. Oncoimmunology, 2015. 4(4): p. e998107.  
14. Wallin, J.J., et al., Atezolizumab in combination with bevacizumab enhances antigen -
specific T -cell migration in metastatic renal cell carcinoma. Nat Commun, 2016. 7: p. 
[ZIP_CODE]. 
15. Larkin J, Rini BI, Nathan P, et al. Phase Ib dose -finding study of avelumab (anti-PD-
L1) + axitinib in treatment- naïve patients with advanced renal cell carcinoma. Ann 
Oncol 2016;27(suppl_6):775PD  
16. Gerullis H, Eimer C, Ecke TH, Georgas E, Arndt C, Otto T. Combined treatment with 
pazopanib and vinflunine in patients with advanc ed urothelial carcinoma refractory 
after first -line therapy. Anti -cancer drugs. 2013 Apr: 24:422- 5 
17. Apolo AB PH, Madan RA, et al. A phase II study of cabozantinib (XL184) in patients 
with advanced/metastatic urothelial carcinoma. J Clin Oncol. 2013: 31: suppl abstr 
[ADDRESS_799729] of cabozantinib on immunosuppressive subsets 
in metastatic urothelial carcinoma. J Clin Oncol 32:5s, 2014 (suppl; abstr 4501). 
19. Yeh CY, Shin SM, Yeh HH, et al. Transcriptional activation of the Ax l and PDGFR -
alpha by c- Met through a ras - and Src -independent mechanism in human bladder 
cancer. BMC Cancer. 11:[ADDRESS_799730]. J Urol. 
2008 Mar: 179:868- 72; discussion 72 
Short Title:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced 
Urothelial Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page 79 of 82 21. Choueiri TK, Ross RW, Jacobus S, et al. Double -blind, randomized trial of docetaxel 
plus vandetanib versus docetaxel plus placebo in platinum -pretreated metastatic 
urothelial cancer. J Clin Oncol. 2012 Feb 10: 30:507- [ADDRESS_799731] of the orally available MET inhibitor PF -
2341066 on tumor burden and metastasis in an orthotopic xenograft model of bladder 
cancer. J  Clin Oncol 29: 2011 (suppl 7; abstr 263)  
23. Linardou H1, Aravantinos G, Efstathiou E, Kalofonos C, Anagnostopoulos A, 
Deliveliotis C, Bafaloukos D, Athanasios Dimopoulos M, Bamias  A; Phase II study 
of Hellenic Co -operative Oncology Group. Gemcitabine and carboplatin combination 
as first -line treatment in elderly patients and those unfit for cisplatin -based 
chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic  Co-
operative Oncology Group. Urology. 2004 Sep;64(3):479- 84. 
24. De Santis M, Wiechno PJ, Bellmunt J, Lucas C, Su WC, Albiges L, Lin CC, Senkus -
Konefka E, Flechon A, Mourey L, Necchi A, Loidl WC, Retz MM, Vaissière N, Culine S. Vinflunine -gemcitabine vers us vinflunine -carboplatin as first -line 
chemotherapy in cisplatin -unfit patients with advanced urothelial carcinoma: results 
of an international randomized phase II trial (JASINT1). Ann Oncol. 2016 Mar;27(3):449- 54. doi: 10.1093/annonc/mdv609. Epub [ADDRESS_799732] J, Saraf S, 
Perini RF, O'Donnell PH . Safety and activity of pembrolizumab in patients with 
locally advanced or metastatic urothelial cancer (KEYNOTE -012): a non-
randomised, ope n-label, phase 1b study. Lancet Oncol. 2017 Feb;18(2):212- 220. doi: 
10.1016/S1470- 2045(17)[ZIP_CODE]- 4. Epub 2017 Jan 10. 
26. R. Nadal, H.L. Parnes, D.C. Francis, L.M. Cordes, M. Berninger, R. Costello, L. 
Folio, M. Linderberg, L. Machado, S.M. Steinberg, J.J. Wright, Y.M. Ning, D.P. 
Bottaro, W.L. Dahut, A.B. Apolo. A phase II study of cabozantinib in patients (pts) with relapsed/refractory metastatic urothelial carcinoma (mUC). Annals of Oncology (2016) 27 (6): 266- 295. 10.1093/annonc/mdw373 
27. Rosa Maria Nadal, Amir Mortazavi, Mark Stein, Sumanta K. Pal, Nicole N. 
Davarpanah, Howard L. Parnes, Yang -Min Ning, Lisa M. Cordes, Mohammadhadi H. 
Bagheri, Liza Lindenberg, Ryan Thompson, Seth M. Steinberg, Tina Moore, Tiffany Lancaster, Milisyaris Velez, Esther Mena, Rene Costello, Donald Bottaro, William L. Dahut, Andrea B. Apolo. Results of phase I plus expansion cohorts of cabozantinib (Cabo) plus nivolumab (Nivo) and CaboNivo plus ipi[INVESTIGATOR_125] (Ipi) in patients (pts) with with metastatic urothelial carcinoma (mUC) an d other genitourinary (GU) 
malignancies. J Clin Oncol 36, 2018 (suppl 6S; abstr 515). 
28. Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., 
Dancey J., Arbuck S., Gwyther  S., Mooney M., Rubinstein L., Shankar, L. Dodd, L. 
Kaplan, R. Lacombe D., Verweij J. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) European Journal of Cancer 2009, 45(2), 228- 247. 
29. Schwartz L. H., Litière S., de Vries E., Forde R., Gwyther S., Mandrekar S., 
Shankarh, L. Bogaerts, J., Chen, A., Dancey J., Hayes W., Hodi S., Hoekstral, O. S., Huang E. P., Lin N., Liu Y., Therasse P., Wolchok J. D., Seymour L. RECIST 1.1—
Short Title:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced 
Urothelial Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page 80 of 82 Update and clarification: From the RECIST committee. European Journal of Cancer 
2016, 62, 132- [ADDRESS_799733]: guidelines for response criteria for use in trials testing immunotherapeutics. The Lancet 18(3), e143- e152 (2017).   
Short Title:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced 
Urothelial Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page 81 of 82 APPENDIX A - Cabozantinib Dosing Diary 
Patient Instructions:  
1) Take the number of pi[INVESTIGATOR_603856] 8oz glass of water at 
approximately the same time each day.  
2) If a pi[INVESTIGATOR_603857], it may be taken as soon as you remember on the same day with a return to normal 
scheduling the following day.  
3) Do not take 2 doses of Cabozantinib  on the same day to try and make up for a missed dose.  
4) Complete one line of the diary each day and write the total number of pi[INVESTIGATOR_603858]. If a dose is missed, indicate “dose not taken”, in the comments briefly explain why , especially noting whether this 
is a dose reduction to every other day administration.  
5) Please bring this diary as well as all empty containers and any unused supplies to your next clinic visit.  
Day Date  Time  Number of 
Pi[INVESTIGATOR_603859] 1      
Day 2      
Day 3      
Day 4      
Day 5      
Day 6      
Day 7      
Day 8      
Day 9      
Day 10      
Day 11      
Day 12      
Day 13      
Day 14      
Day 15      
Day 16      
Day 17      
Day 18      
Day 19      
Day 20      
Day 21      
Day 22      
Day 23      
Day 24     
Day 25      
Day 26      
Day 27      
Day 28      
  Patient Signature _ ________ ____________________________________ Date______________________  
Short Title:  Cabozantinib plus P embrolizumab as F irst-Line Therapy for C isplatin -Ineligible Advanced 
Urothelial Carcinoma (PemCab)   
Version Date:  30MAR2022  
Page 82 of 82 APPENDIX B - Stool Sample Collection Questionnaire  
 
               Stool Collection Questionnaire  
Date Collected: 
Time Collected: 
Dietary Questionnaire  
In the last week: 
How often did you consume red meat? 
Never ☐  Once ☐  2 – 5 times ☐  Daily ☐ 
How often did you consume desserts, sweets, soda, or juice? 
Never ☐  Once ☐  2 – 5 times ☐  Daily ☐ 
How often did you consume high fiber foods? 
Fresh vegetables? Never ☐  Once ☐  2 – 5 times ☐  Daily ☐ 
Whole grains*? Never ☐   Once ☐   2 – 5 times ☐  Daily ☐  
Fresh Fruit? Never ☐  Once ☐  2 – 5 times ☐  Daily ☐ 
*Examples include oatmeal, quinoa, brown/wild rice, barley, whole-wheat products. For the use of the Huntsman Cancer Institute, study coordinator 
Time -point:  
Study ID:  
Study Name:  
 
